# Table of contents

Introduction ........................................................................................................................................... 6

A  Business and performance .................................................................................................................. 7
    A.1 Business .......................................................................................................................................... 7
        A.1.1 Profile ....................................................................................................................................... 8
        A.1.2 General information .................................................................................................................. 12
    A.2 Underwriting performance ............................................................................................................ 13
    A.3 Investment performance ............................................................................................................... 14
        A.3.1 Financial assets and derivatives ............................................................................................... 14
        A.3.2 Company statement of comprehensive income ........................................................................ 15
        A.3.3 Information about investments in securities ............................................................................ 15
    A.4 Performance of other activities ..................................................................................................... 16
    A.5 Any other information ................................................................................................................... 16

B  System of governance ........................................................................................................................ 17
    B.1 General information on the system of governance ...................................................................... 17
        B.1.1 Corporate governance .............................................................................................................. 17
        B.1.2 Remuneration report .............................................................................................................. 19
        B.1.3 Related-party transactions ..................................................................................................... 22
        B.1.4 Remuneration of Supervisory Board and Executive Board ..................................................... 22
    B.2 Fit and proper requirements .......................................................................................................... 24
    B.3 Risk management system including the own risk and solvency assessment
        Risk Management System .............................................................................................................. 24
        B.3.1 Enterprise Risk Management Framework ............................................................................... 24
        B.3.2 a.s.r.’s risk categories .............................................................................................................. 32
    B.4 Internal control system .................................................................................................................. 34
        B.4.1 Strategic and operational risk management ............................................................................. 34
        B.4.2 Compliance function ................................................................................................................. 35
    B.5 Internal audit function ................................................................................................................... 36
    B.6 Actuarial function .......................................................................................................................... 36
    B.7 Outsourcing .................................................................................................................................... 37
    B.8 Any other information ................................................................................................................... 38

C  Risk profile ........................................................................................................................................ 39
    C.1 Insurance risk ............................................................................................................................... 43
D.2.6 Reconciliation between IFRS and Solvency II .......................................................... 64
D.3 Other liabilities .............................................................................................................. 64
D.3.1 Valuation of other liabilities .................................................................................. 64
D.3.2 Reconciliation from Solvency II equity to EOF ...................................................... 65
D.4 Alternative methods for valuation ............................................................................... 65
D.5 Any other information ................................................................................................. 65
E Capital management ....................................................................................................... 66
E.1 Own funds ................................................................................................................... 67
  E.1.1 Capital management objectives ............................................................................. 67
  E.1.2 Tiering own funds ................................................................................................. 68
  E.1.3 Own funds versus MCR ....................................................................................... 68
  E.1.4 Description of grandfathering ............................................................................. 68
E.2 Solvency Capital Requirement .................................................................................... 68
E.3 Use of standard equity risk sub-module in calculation of Solvency Capital Requirement .................................................. 69
E.4 Differences between Standard Formula and internal models .................................... 69
E.5 Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement ........................................................................................................ 69
E.6 Any other information ................................................................................................. 69
  E.6.1 Dividend policy and capital actions ...................................................................... 69
Introduction

The structure of the Solvency and Financial Condition Report (SFCR) has been prepared as described in annex XX of the Solvency II Directive Delegated Acts. The subjects addressed are based on article 51 to 56 of the Solvency II Directive and act 292 up to and including 298 of the Delegated Acts. Furthermore, the figures presented in this report are in line with the supervisor’s reported Quantitative Reporting Templates.

All amounts in this report are presented in thousands of euros (€ thousand), being the functional currency of ASR Basis Ziektekostenverzekeringen N.V. All amounts quoted in the tables contained in this report are in thousands of euros (€), unless otherwise stated.

Referring to Solvency, 2015 figures are not presented here, as Solvency II replaced Solvency I as at 1 January 2016, which makes a comparison of these two years not useful.
A Business and performance

A.1 Business

Eligible own fund 2016

The key figures of ASR Basis Ziektekostenverzekeringen N.V. are presented below. These figures give a short overview of the composition of the Eligible Own Funds (EOF) from a tiering perspective, the composition of the required capital following Solvency II and the reconciliation from IFRS equity to Solvency II EOF.

SCR 2016

The solvency ratio stood at 144% as at 31 December 2016 based on the standard formula as a result of €131,536 thousand EOF and €91,158 thousand SCR.
Reconciliation total equity IFRS vs EOF Solvency II

<table>
<thead>
<tr>
<th>Total equity IFRS</th>
<th>Revaluation of other assets (-/-)</th>
<th>Revaluation of the technical provisions</th>
<th>Subordinated liabilities and foreseeable dividends</th>
<th>Eligible own funds Solvency II</th>
</tr>
</thead>
<tbody>
<tr>
<td>114,325</td>
<td>-635</td>
<td>7,845</td>
<td>10,000</td>
<td>131,536</td>
</tr>
</tbody>
</table>

An extensive explanation of the reconciliation from IFRS equity to Solvency II EOF is presented in section D.

A.1.1 Profile

Object of the company
ASR Basis Ziektekostenverzekeringen N.V. aims to promote the health of its customers and improve healthcare. ASR Basis Ziektekostenverzekeringen N.V. helps its customers in a personal, expert and reliable manner. ASR Basis Ziektekostenverzekeringen N.V. focuses on adding customer value and building a financially robust and effective organization. This ensures that customers know what they can count on with complete peace of mind.

ASR Basis Ziektekostenverzekeringen N.V. offers health insurance to all individuals who are entitled to health insurance under the Dutch Health Insurance Act.

Core activities
The core activity of ASR Basis Ziektekostenverzekeringen N.V. is the implementation of the Health Insurance Act. As a national health insurer, ASR Basis Ziektekostenverzekeringen N.V. offers basic health insurance. As well as basic health insurance, ASR Nederland N.V. (hereinafter also called a.s.r.), of which ASR Basis Ziektekostenverzekeringen N.V. is a constituent part, offers supplementary health insurance via ASR Aanvullende Ziektekostenverzekeringen N.V. In addition, a new legal entity was set up on 1 January 2016 for the implementation of the Dutch Chronic Care Act (Dutch acronym: Wlz). ASR Wlz-uitvoerder B.V. is a Wlz service provider without a care administration office. In 2016, ASR Basis Ziektekostenverzekeringen N.V. had 340,985 insured customers.

In 2016, the healthcare market was served by two labels: De Amersfoortse and Ditzo. Whilst sharing certain values that are common to the group, each of the brands has a clearly defined role of its own. De Amersfoortse specializes in health insurance for business owners (SMEs) and self-employed people. Distribution takes place via the intermediary channel. Ditzo caters to price- and quality-conscious customers via the direct online channel and online healthcare comparison sites. Free access to any physician of preference is an important principle of both brands of ASR Basis Ziektekostenverzekeringen N.V. In addition to its own brands, health insurance is also provided through underwriting agencies (IAK Volmacht B.V., Aevitae B.V. and Caresco B.V.).

Legal structure of the company
ASR Basis Ziektekostenverzekeringen N.V. is a wholly owned (100%) subsidiary of ASR Ziektekostenverzekeringen N.V., which is a wholly owned (100%) subsidiary of ASR Nederland N.V (a.s.r.).

a.s.r. became a listed company following an Initial Public Offering (IPO) on 10 June 2016. Stichting Administratiekantoor Beheer Financiële Instellingen (NLFI), placed the shares in the market. The shares are listed on Euronext Amsterdam (symbol ASRNL) and have been included in the AMX index (Amsterdam Midcap Index) since 19 September 2016. On 31 December 2016, NLFI held 63.7% of a.s.r. shares. Before the IPO on 2016, NLFI held 100% of a.s.r. shares. In 2017 NLFI reduced its position in a.s.r. to 36.8%.
Internal organisation structure

In 2016 ASR Basis Ziektekostenverzekeringen N.V. was divided into the following organizational units: Operations, Healthcare, Contact Centre, Information Management, and Finance, Risk and Control. Operations comprises the Medical Expenses Acceptance and Debt Management. Healthcare can be subdivided into Healthcare Expense Claims, Care for Care, Procurement, and Policy and Consultancy. Information Management comprises Team Data, Healthcare Project Management and IT Service.

Organizational chart

Below, the organizational chart of ASR Basis Ziektekostenverzekeringen N.V. is presented:

Staffing

All employees are on the payroll of a.s.r. The employees of a.s.r. work for both ASR Basis Ziektekostenverzekeringen N.V. and ASR Aanvullende Ziektekostenverzekeringen N.V. In 2016, the headcount of internal employees rose from 113.3 FTEs to 143 FTEs. This increase was mainly due to the migration of the employees of Accounts Receivable Management as well as the colleagues of Project Management and Service Chain to a.s.r. Ziektekosten effective from 1 January 2016. As in previous years, the company operated with a relatively large flexible layer next to internal employees to absorb the extra work arising from the health insurance switching season.

In 2016 a change in the Executive Board took place within ASR Basis Ziektekostenverzekeringen N.V. Ms P.H. van Holst opted to continue her career at the Association of Dutch Health Insurers and Ms J.D. Lansberg was appointed Director of Health Insurance Business, alongside Mr J.M. Hendriks.

The composition of the Supervisory Board (SB) of ASR Basis Ziektekostenverzekeringen N.V. is as follows: C. van der Pol (chairman), A.P. Aris, J.P.M. Baeten and M.H. Verwoest. The composition of the Supervisory Board remained unchanged in 2016.
Key elements of the pursued policy

ASR Basis Ziektekostenverzekeringen N.V. has the ambition to be the most personal health insurer and to deliver a positive brand experience for the a.s.r. labels. The rising Net Promoter Score (NPS) for customer contacts in 2016 reflects this ambition. The increase was achieved by listening carefully to the wishes of customers alongside ongoing efforts to improve the quality of services. At the front-end of the organization, the further digitization of information and delivery of Standard Operating Procedures (SOPs) has led to enhanced uniformity and quality of information. Our efforts in the back-office focused on further staff specialization to make the organization more efficient and customer-focused.

In recent years, the procurement of healthcare was outsourced to Multizorg VRZ B.V. Last year, ASR Basis Ziektekostenverzekeringen N.V. conducted an evaluation to see whether this partnership still matched the corporate objectives. As a result, the Partnership Agreement with Multizorg was terminated and replaced by a new Partnership Agreement with DSW Zorgverzekeraar N.V. in which ASR Basis Ziektekostenverzekering N.V. will take on a more leading role in procurement. This new approach is expected to deliver more competitive and distinctive procurement results for ASR Basis Ziektekostenverzekeringen N.V.

Last year, a new De Amersfoortse product ('Doorgaanverzekering') was developed to boost the distinctiveness of ASR Basis Ziektekostenverzekeringen N.V. This product offers a unique combination of Health and Income insurance. Two specific modules have been developed. One Doorgaan module is for business owners and provides extra cover aimed at absenteeism prevention and rapid re-integration. Attractive components for business owners include extra compensation for physiotherapy and psychological care, while employees receive extra compensation for specific ailments. The second module is for employees and contains extra care for e.g. oncology, strokes and family-related care. Another product launched this year was Pechvogelhulp. Ditzo offers this extra service to all its health insurance customers in 2017. Pechvogelhulp gives customers who have suffered an accident in the Netherlands extra coverage for medical expenses up to € 10,000. This concerns costs that are not covered by the basic or supplementary health insurance package.

ASR Basis Ziektekostenverzekeringen N.V. is aware of its social responsibility as a health insurer. Various initiatives testify to this awareness. For instance, instead of conducting an expensive television marketing campaign for the 2017 health insurer switching season, it has decided to return this money to customers in the form of a lower premium. Finally, ASR Basis Ziektekostenverzekeringen N.V. once again achieved further growth. The number of insured persons rose from 2016 to 2017 by 8.6%.

One remarkable event for ASR Basis Ziektekostenverzekeringen N.V. was the IPO of ASR Nederland. ASR Basis Ziektekostenverzekeringen N.V. is the only health insurer belonging to a listed organization. The process surrounding the IPO prompted a further focus on customer satisfaction, costs and solvency in order to ensure that ASR Basis Ziektekostenverzekeringen N.V. can remain a robust health insurer. In accordance with the Articles of Association, ASR Basis Ziektekostenverzekeringen is a not-for-profit organization and does not pay out dividend to ASR Nederland N.V.

Market and distribution developments

Market developments

The media and comparison sites have strong influence on customer behaviour. In 2016, the advertising budgets of health insurers came under scrutiny in the debate about medically necessary spending. As a result, the issues of access to any physician of preference and compulsory use of contracted health services attracted less attention. The number of switchers dropped in 2016 to 6.4% compared to 6.8% in 2015.

The exit survey showed that access to any physician of preference and the certainty of contracted care are subordinate to price in the customer’s decision-making process. Customers search for information online, mainly on comparison websites and websites of online providers. Comparison sites concentrate on price, the extent of access to any physician of preference (contracting & quality of care) and also the cover provided.

Ditzo stands out from other players by refraining from mass marketing campaigns. Ditzo prefers to approach customers through online social media, often centring on social themes that resonate with the target group. At product level, Ditzo meets the wishes of customers by offering a good premium combined with access to any physician of preference. In addition to this proposition, Ditzo offers fast and extensive online services. To keep their individual premium low, the insured often opts for a higher deductible and no or less supplementary insurance.
Distribution developments
Alongside online insurers, intermediaries who use comparison sites or offer online health insurance as underwriting agents play a dominant role in the distribution of health insurance. This is broadly similar to the picture in 2015.

Ditzo
The Ditzo label offers services to customers via the direct channel. Ditzo does this in collaboration with comparison sites and affiliated parties. The Pechvogel module was launched ahead of the 2017 health insurance switching season.

De Amersfoortse
De Amersfoortse is the label that offers its propositions via the intermediary channel. The focus here is on cooperation with the advisers who best match the various customer groups. The account managers play a key role in this connection. Intermediaries increasingly realize that healthcare is becoming more important in the advisory model, notably in the business market. This forms part of the trend towards lifelong employability. De Amersfoortse brand of ASR Basis Ziektekostenverzekeringen N.V. specifically serves the SME niche market.

Internal control of processes and procedures
Adequate risk management within ASR Basis Ziektekostenverzekeringen N.V. is essential to control the quality of processes and procedures and keep improving operational performance. The result is increased customer satisfaction, as is reflected in, among other things, the Customer-Focused Insurance Quality Mark (KKV).

The effectiveness of the most important control measures is tested from time to time. The use of a Comprehensive Risk Management Framework gives ASR Basis Ziektekostenverzekeringen N.V. a grip on its overall risk profile and facilitates responsible risk management.

Insight into the size and interconnectedness of risks enables ASR Basis Ziektekostenverzekeringen N.V. to accept risks that are responsible and consistent with the associated reward. Comprehensive risk management thus supports the preservation of financial robustness.

Alongside the periodic testing of the key controls by means of a Comprehensive Risk Management framework, our risk management is also supported by the performance of Control Risk Self-Assessments (CRSA), Own Risk and Solvency Assessments (ORSA), operational loss monitoring and project risk assessments.

New products and services and accompanying customer brochures undergo an internal ‘Product Approval and Review Process (PARP)’.

At ASR Basis Ziektekostenverzekeringen N.V., claims are monitored retrospectively for the following control domains: formal, material, medical necessity and fraud. A separate department (‘Zorgcontrole’) has been set up for this purpose. In 2016, a project was carried out to improve the billing chain by building more prospective formal controls into the systems and thus reduce the need for retrospective corrections. Outcomes of investigations and checks help to reduce and prevent billing of fraudulent and/or medically unnecessary claims. Ultimately, ASR Basis Ziektekostenverzekeringen N.V. is accountable to the Dutch Healthcare Authority (NZa). For the reporting year 2016, NZa found no noteworthy shortcomings in the internal processes or in the ZIN (National Health Care Institute) reports.

Quality control
ASR Basis Ziektekostenverzekeringen N.V. wants to be the most personal health insurer offering excellent services to its customers. To this end, an extensive quality management system has been set up, outlining how ASR Basis Ziektekostenverzekeringen N.V. wants to serve its customers. Based on the norms and standards contained in the quality policy, ASR Basis Ziektekostenverzekeringen N.V. actively seeks to fulfill the quality requirements for customer-focused insurance, continuous process improvement in all departments, staff training and the retention of the Customer-Focused Insurance Quality Mark.

KPIs have been defined to actively monitor the achievement of these objectives. The progress and results on these KPIs are periodically shared within ASR Basis Ziektekostenverzekeringen N.V.

ASR Basis Ziektekostenverzekeringen N.V. greatly values the feedback from its customers. NPS measurements were performed in the 1st and 2nd line in 2016 to obtain even better insight into what customers think of our information, response,
and the quality of our customer contacts in general. This feedback was used to improve the processes and train our employees.

The ambition in the field of services to customers was translated into the achievement of a positive NPS score for customer contact.

The number of new complaints is falling and was 19% lower than in 2015. The NPS method is also used to ask customers for feedback on our complaints handling process.

To further improve our service to customers, our medical billing department has been reorganized to process claims by type of healthcare. Employees can now specialize much more in specific types of healthcare, leading to improved quality of service.

In 2016, ASR Basis Ziektekostenverzekeringen N.V. commenced the roll-out of its new customer contact strategy. This is aimed at enabling customers to contact us through the channel that suits them best. In addition, a very extensive dialogue manager was introduced so that customers are now better able to find the correct information on our websites.

In 2016 several customer journeys were performed. Examples include the ‘deductible’ and ‘complaints’ customer journeys. The outcomes of both customer journeys were used to improve our services, for instance through the introduction of spread deductible payments from 1 January 2017 and improvements to the complaints aftercare process.

ASR Basis Ziektekostenverzekeringen N.V. conducts a yearly customer satisfaction survey. The outcomes and resulting points for improvement are shared with our customers via the website.

In 2016 the Customer Centric Insurance Foundation carried out a customer contact audit. The resulting recommendations enable ASR Basis Ziektekostenverzekeringen N.V. to focus even more on the interests of our customers.

Finance

As an insurer, a.s.r., and hence also a.s.r. Basis Ziektekostenverzekeringen N.V., has a relatively limited financing requirement. As a result, a.s.r. Basis Ziektekostenverzekeringen N.V. makes limited use of money and capital markets. This is consistent with the prudent policy and financial robustness that a.s.r. aspires for. a.s.r. has ample resources and flexibility to meet its minimal financing requirements in an appropriate manner. Due to the relatively limited funding requirements, combined with the options for raising secured financing, a.s.r. currently has ample liquid assets to carry out its operations.

A.1.2 General information

The Solvency and Financial Condition Report is presented in thousands of euros (€), being the functional currency of ASR Basis Ziektekostenverzekeringen N.V. All amounts quoted in the tables contained in these SFCR are in thousands of euros, unless otherwise indicated.

The SFCR has been prepared by and is the sole responsibility of the Company’s management. Selected Own Funds and SCR information are also reported in a.s.r. financial statements. EY has examined the 2016 financial statements and issued an report thereon.

The SFCR has been prepared by and are the sole responsibility of the Company’s management. Selected Own Funds and SCR information are also reported in a.s.r. financial statements.

Name and contact details of the supervisory authority

Name: De Nederlandsche Bank
Visiting address: Westeinde 1, 1017 ZN Amsterdam
Phone number (general): +31 800 020 1068
Phone number (business purposes): +31 20 524 9111
Email: info@dnb.nl
A.2 Underwriting performance

Key figures
- Profit for the year at €16,297 thousand (2015: €3,504 thousand)
- Gross written premiums up, rising to €544,117 thousand (2015: €515,631 thousand)
- Operating expenses down 9.4% to €20,372 thousand (2015: €22,489 thousand)
- Combined ratio at 97.6% (2015: 100.3%)

<table>
<thead>
<tr>
<th>Key figures ASR Basis Ziektekostenverzekeringen N.V. separate (x €1,000)</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross new business</td>
<td>53,107</td>
<td>54,716</td>
</tr>
<tr>
<td>Gross written premiums</td>
<td>544,117</td>
<td>515,631</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>20,372</td>
<td>22,489</td>
</tr>
<tr>
<td>Profit/(loss) before taxes</td>
<td>21,729</td>
<td>4,672</td>
</tr>
<tr>
<td>Income tax expense</td>
<td>5,432</td>
<td>1,168</td>
</tr>
<tr>
<td>Profit/(loss) for the year</td>
<td>16,297</td>
<td>3,504</td>
</tr>
<tr>
<td>Claims ratio</td>
<td>92.9%</td>
<td>95.4%</td>
</tr>
<tr>
<td>Expense ratio</td>
<td>4.7%</td>
<td>4.9%</td>
</tr>
<tr>
<td>Combined ratio</td>
<td>97.6%</td>
<td>100.3%</td>
</tr>
</tbody>
</table>

Gross new business
The Ditzo customer portfolio grew further in 2016, driven by customers choosing for the combination of a good price and access to any physician of preference. Gross new business was €53,107 thousand (2015: €54,716 thousand), with 81% coming from Ditzo Zorg (2015: 90%). In 2016, De Amersfoortse achieved portfolio growth for the first time in some years. The new Doorgaan proposition contributed to this performance. In 2016, almost 65,000 new customers (2015: almost 67,000) opted for one of the two labels of ASR Basis Ziektekostenverzekeringen N.V.

Gross written premiums
Gross written premiums rose to €544,117 thousand (2015: €515,631 thousand). The increased revenue arising from the portfolio growth at Ditzo and De Amersfoortse was partly offset by a decline in the equalization contribution compared to 2015.

Operating expenses
Operating expenses stood at €20,372 thousand (2015: €22,489 thousand). The decline is largely attributable to lower operating expenses due to tight cost controls. In addition, Costs per Acquisition (CPA) were transferred in 2016 from operating expenses to commission costs.

Profit/(loss) for the year
Profit for the year before taxes came to €21,729 thousand in 2016, up €17,057 thousand on 2015. This is mainly due to an improvement of the insurance result, lower operating expenses and lower other income and expenses, notably because a bad debt provision was formed for Underwriting Agents and Healthcare Institutions in 2015. As in previous years, a premium shortfall provision was formed as positive results from the past are returned to the customer in the form of a lower premium than is actuarially required. In addition, ASR Basis Ziektekostenverzekeringen N.V. uses profits to grow the portfolio while preserving a good Solvency II position.
Key figures
The claims ratio and combined ratio decreased compared to last year.

Solvency and liquidity on balance sheet date
Equity rose from €99,585 thousand at year-end 2015 to €114,325 thousand at year-end 2016. The profit achieved in 2016 was partly offset by a decrease in the revaluation reserve at fixed rate value of €1,557 thousand.

Solvency II took effect on 1 January 2016. The Solvency II ratio decreased by 1 percentage points to 144.2% (day-one 2016: 145.6%). The Solvency II ratio decreased from day-one 2016 mainly due to accretion driven by LACDT guidance.

A.3 Investment performance
ASR Basis Ziektekostenverzekeringen N.V.’s investment policy is aimed at striking a balance between generating returns and preventing risks. Protecting the solvency position is an important factor in this context.

A.3.1 Financial assets and derivatives
Financial assets and derivatives can be broken down as follows:

<table>
<thead>
<tr>
<th></th>
<th>31 December 2016</th>
<th>31 December 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Available for sale</td>
<td>269,524</td>
<td>336,087</td>
</tr>
<tr>
<td>Loans and receivables</td>
<td>127,753</td>
<td>105,503</td>
</tr>
<tr>
<td>Derivatives assets</td>
<td>51</td>
<td>-</td>
</tr>
<tr>
<td>Derivatives liabilities</td>
<td>-</td>
<td>-18</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>1,549</td>
<td>1,199</td>
</tr>
<tr>
<td>Total</td>
<td>398,877</td>
<td>442,771</td>
</tr>
</tbody>
</table>

For more detailed information about the fair value valuation of the financial assets and derivatives, please refer to chapter 2.6.2 of the annual report.

There is a small portfolio of derivatives to cover some investment risks.

The table below gives a detailed overview of the types of financial assets and derivatives held:

<table>
<thead>
<tr>
<th></th>
<th>31 December 2016</th>
<th>31 December 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equities</td>
<td>6,230</td>
<td>5,858</td>
</tr>
<tr>
<td>Fixed-interest securities</td>
<td>263,294</td>
<td>330,229</td>
</tr>
<tr>
<td>Loans and receivables</td>
<td>127,753</td>
<td>105,503</td>
</tr>
<tr>
<td>Derivatives assets</td>
<td>51</td>
<td>-</td>
</tr>
<tr>
<td>Derivatives liabilities</td>
<td>-</td>
<td>-18</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>1,549</td>
<td>1,199</td>
</tr>
<tr>
<td>Total</td>
<td>398,877</td>
<td>442,771</td>
</tr>
</tbody>
</table>

Investment income
The table below shows a breakdown of investment income per category:
Interest income and dividend and other investment income are presented in the table below:

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest income</td>
<td>3,179</td>
<td>4,392</td>
</tr>
<tr>
<td>Dividend and other</td>
<td>171</td>
<td>116</td>
</tr>
<tr>
<td>investment income</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total investment income</strong></td>
<td><strong>3,350</strong></td>
<td><strong>4,508</strong></td>
</tr>
</tbody>
</table>

The table below breaks down interest income per category:

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest income from investments</td>
<td>3,108</td>
<td>4,374</td>
</tr>
<tr>
<td>Interest income from amounts due from customers</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>Other interest income</td>
<td>71</td>
<td>8</td>
</tr>
<tr>
<td><strong>Total interest income</strong></td>
<td><strong>3,179</strong></td>
<td><strong>4,392</strong></td>
</tr>
</tbody>
</table>

The effective interest method has been applied to an amount of € 3,108 thousand of the interest income from financial assets not classified at fair value through profit and loss (2015: € 4,374 thousand).

Interest income includes € 206 thousand (2015: € 25 thousand) in interest received on impaired fixed-income securities.

Dividend and other investment income per category can be broken down as follows:

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dividend on equities</td>
<td>171</td>
<td>116</td>
</tr>
<tr>
<td><strong>Total dividend and other investment income</strong></td>
<td><strong>171</strong></td>
<td><strong>116</strong></td>
</tr>
</tbody>
</table>

### A.3.2 Company statement of comprehensive income

(in € thousands)

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Profit for the year</td>
<td>16,297</td>
<td>3,504</td>
</tr>
<tr>
<td>Unrealized change in value of available-for-sale financial assets</td>
<td>-2,076</td>
<td>-6,394</td>
</tr>
<tr>
<td>Income tax on items that may be reclassified subsequently to profit and loss</td>
<td>519</td>
<td>1,598</td>
</tr>
<tr>
<td><strong>Total items that may be reclassified subsequently to profit and loss</strong></td>
<td><strong>-1,557</strong></td>
<td><strong>-4,796</strong></td>
</tr>
<tr>
<td>Total other comprehensive income for the year, after tax</td>
<td>-1,557</td>
<td>-4,796</td>
</tr>
<tr>
<td><strong>Total comprehensive income</strong></td>
<td><strong>14,740</strong></td>
<td><strong>-1,292</strong></td>
</tr>
</tbody>
</table>

The numbers following the line items refer to the relevant chapters in the notes of the annual report.

### A.3.3 Information about investments in securities

As ASR Basis Ziektekostenverzekeringen N.V. has no investments in securitization, no further information is included here.
A.4 Performance of other activities

No other activities are material.

A.5 Any other information

No other information is applicable.
B System of governance

In the case where the text below refers to ‘the company’, ASR Basis Ziektekostenverzekeringen N.V. is meant.

B.1 General information on the system of governance

B.1.1 Corporate governance

This paragraph contains a description of group policy, which is applicable for the solo entity. ASR Basis Ziektekostenverzekeringen N.V. has its own governance structure, which is described below. On top of this, ASR Basis Ziektekostenverzekeringen N.V. uses the facilities of the Group and has its own supervisory and executive board.

B.1.1.1 Supervisory Board Committees

Audit and Risk Committee
The Supervisory Board did not institute an Audit and Risk Committee. Audit and risk issues are discussed during a separate part of every meeting of the Supervisory Board.

Selection, Appointment and Remuneration Committee
The Supervisory Board did not institute a Selection, Appointment and Remuneration Committee.

B.1.1.2 Corporate Governance

ASR Basis Ziektekostenverzekeringen N.V. is a limited liability company. The company has a two-tier board; a Supervisory Board and an Executive Board. The General Meeting of Shareholders is authorized to appoint and dismiss members of the Executive Board and the Supervisory Board.

B.1.1.3 Supervisory Board

The Supervisory Board supervises the policy pursued by the Executive Board and the general course of affairs at ASR Basis Ziektekostenverzekeringen N.V. and advises the Executive Board. Specific powers are vested in the Supervisory Board, including the approval of certain decisions taken by the Executive Board.

Composition
The Supervisory Board of ASR Basis Ziektekostenverzekeringen N.V. consists of four members: C. van der Pol (chairman), A.P. Aris, J.P.M. Baeten and M.H. Verwoest. The Supervisory Board has drawn up a profile for its size and composition, taking into account the nature of ASR Basis Ziektekostenverzekeringen N.V.’s business, its activities and the desired expertise and background of the Supervisory Board members.

The composition of the Supervisory Board is such that each supervisory director should have the skills to assess the main aspects of the overall policy and that the Supervisory Board as a whole meets the profile thanks to a combination of the experience, expertise and independence of the individual supervisory directors. The Supervisory Board is diverse in terms of the gender and professional background of its members. The diversity of its members ensures the complementary profile of the Supervisory Board.

Education and evaluation Supervisory Board of the Group

The Supervisory Board performs a self-assessment annually. The following aspects were assessed in the 2016 assessment:

- Composition of the Supervisory Board:
  - strengths and weaknesses;
  - Effectiveness of the Supervisory Board processes:
  - information-gathering, decision-making and focus on core themes;
  - Advisory role to the Executive Board on important subjects;
  - Role of employer: strengths and weaknesses.

The overall impression that emerged from this self-assessment was positive.
Two continuing education (CE) sessions were organized for the members of the Supervisory Board in 2016. The first session for the Supervisory Board was about the risks and changes of global warming for the Insurance Industry. During the other session the Supervisory Board was educated and caught up about the impact of exponential technology on insurance business management and strategy.

Independence and conflicts of interest
There were no reports of potential conflicts of interest by the other supervisory directors. The Supervisory Board has been able to exercise its tasks completely independently.

B.1.1.4 Executive Board
The Executive Board is responsible for the day-to-day conduct of business of ASR Basis Ziektekostenverzekeringen N.V. and for the strategy, structure and performance. In performing their duties the Executive Board is guided by ASR Basis Ziektekostenverzekeringen N.V.’s interests, which include the interests of the business connected with ASR Basis Ziektekostenverzekeringen N.V., which, in turn, include the interests of customers, insurers, employees and, in general, the society in which ASR Basis Ziektekostenverzekeringen N.V.’s business is carried out. The Executive Board is accountable for the performance of its duties to the Supervisory Board and to the General Meeting.

Composition
The Executive Board will consist of a minimum of two members. The General Meeting of Shareholders appoints the Executive Board members and may at any time suspend or dismiss any member of the Executive Board. Only candidates found to meet the fit and proper test under the Dutch Financial Markets Supervision Act are eligible for appointment. In 2016 Mrs P.H. van Holst-Wormser resigned as Executive Board member (with effect from 1 April) and Mrs. J.D. Lansberg has been appointed as Executive Board member (with effect from 1 September). Between 1 April and 1 September M.H. Verwoest acted as an executive Board member. During this period M.H. Verwoest was not a member of the Supervisory Board.

Education and evaluation Executive Board
The members of the Executive Board took individual courses in 2016 as part of their continuing education (CE). In addition, much attention was devoted to knowledge-building in the areas of capital management and innovation, as well as to interesting developments, including the impact of political decisions on the potential business models of health care insurers in The Netherlands.

The decision making process of the Executive Board was self-evaluated in 2016. Focus was on effective decision-making and information gathering. The outcomes of the evaluation were discussed with the deputy directors. The overall impression was positive. A few improvements were made in the organization and reporting of the Board Meeting.

In addition to the self-evaluation, the performance of the members of the Executive Board was also assessed by the Supervisory Board within the scope of the annual assessment round.

The multi-year budget 2017-2019, the investment plan and the risk priorities for 2017 were discussed at length at the end of the reporting year, after which the multi-year budget was adopted by the Supervisory Board of a.s.r. and ASR Basis Ziektekostenverzekeringen N.V.

B.1.1.5 Regulations
Professional oath
As of 1 January 2013 a mandatory oath for Executive and Supervisory Board members of financial institutions licensed in the Netherlands was introduced. The Executive Board and Supervisory Board members of all financial undertakings that are licensed in the Netherlands must take this mandatory oath. In this oath, board members declare that they will: (a) perform their duties with integrity and care, (b) carefully consider all the interests involved in the financial institution, i.e. those of the customers, the shareholders, the employees and the society in which it operates, (c) in doing so, give paramount importance to the customer’s interests and inform the customer to the best of their ability, (d) comply with the laws, regulations and codes of conduct applicable to them, (e) observe confidentiality in respect of matters entrusted to them, (f) not abuse their knowledge, (g) act in an open and assessable manner and know their responsibility towards society, and (h) endeavour to maintain and promote confidence in the financial sector. If the oath is broken, the supervisory authority (DNB/AFM) can decide to reassess their suitability.

With respect to insurance companies, apart from the Executive and Supervisory Board members, persons with a management position directly below the Executive Board that are responsible for persons that may have a significant
influence on the risk profile of the insurance company, are also required to take the oath, as are certain other employees. This includes persons that may (independently) significantly influence the risk profile of the undertaking as well as those persons that are or may be involved in the provision of financial services.

Regardless of the above, ASR Basis Ziektekostenverzekeringen N.V. has decided that employees and other persons performing activities under its responsibility must take the oath.

All employees have taken the oath before 1 April 2016. New employees take the oath within 3 months.

B.1.2 Remuneration report

Improving and maintaining the integrity and robustness of a.s.r. is key to the remuneration policy, and the focus is squarely on the long-term interests of all our stakeholders. The aim of the remuneration policy is to motivate employees to work for the interests of customers and other stakeholders within the parameters of the duty of care.

Due to the large financial responsibility Dutch health care insurers have, because of the compulsory nature of the insurance special regulation for remuneration are in place. The Standardization of Top Incomes Act aims at creating maximum transparency and reasonable incomes for board members of government institutions, but also affects the board members of health insurers. ASR Basis Ziektekostenverzekeringen N.V. is compliant with this legislation.

The remuneration policy is based on the following a.s.r. Group remuneration principles.

1. HR policy:
   • The remuneration policy strikes a balance between trust in intrinsic motivation on the one hand and agreement on clear targets and assessment of performance on those targets on the other.
   • The total pay-and-benefits package enables the company, to a certain maximum, to compete in the labour market and to attract and retain competent people.

2. Sound remuneration policy:
   • The remuneration policy, including the pension policy, ties in with the corporate strategy and with the company’s objectives, values and long-term interests. Any changes in strategy, objectives, values and long-term interests are taken into account when updating the remuneration policy.
   • The remuneration policy is ethical, sound and sustainable, in line with the company’s risk appetite, risk management strategy and risk profile, contributes to robust and effective risk management, and does not encourage a greater risk appetite than is acceptable to the business.
   • The remuneration policy has been designed in such a way that allowance is made for the internal workings of the company, its subsidiaries and group companies, and for the nature, scale and complexity of the risks attached to the business.
   • The remuneration policy does not restrict the company’s scope to maintain and strengthen its robust regulatory capital, solvency margin or own funds.

3. Protection of customers and safeguarding integrity and long-term enterprise value:
   • The remuneration policy encourages employees to act in accordance with the company’s long-term interests.
   • The remuneration policy has been designed in such a way that consumers, clients or members are treated with due care.
   • Performances delivered by employees and by the company itself are measured on the basis of both financial and non-financial indicators.
   • The remuneration policy does not encourage employees to take excessive risks.
   • The remuneration policy seeks to prevent conflicts of interest.
   • The company does not apply constructions or methods that facilitate the evasion of the remuneration policy or the relevant legislation and regulations.
   • Employees are expected not to make use of personal hedging strategies or of any insurance policies linked to remuneration and liability to undermine the risk management effects embedded in their remuneration schemes.

4. Transparency:
   • The design, governance and methodology of the remuneration policy are clear, transparent and applicable to all employees.
5. Compliance:
- The remuneration policy complies with prevailing national and international legislation and regulations (see also Section 1.4). It is evaluated periodically and modified, if necessary, to ensure compliance with new legislation and regulations or market standards.
- The compliance of the remuneration policy and the related procedures with the relevant rules and regulations is checked at least once a year by a centralized and independent internal body.

Governance
- The Annual General Meeting (AGM) has decision-making powers relating to the remuneration policy of the Executive Board and the individual remuneration of the supervisory directors. In addition, the Supervisory Board informs the AGM of the individual remuneration of the executive directors.
- The Supervisory Board has decision-making powers relating to setting the individual remuneration of the members of the Executive Board. In addition, the Supervisory Board has responsibilities regarding, the remuneration policy for all groups of employees and monitors same. The Supervisory Board also approves the remuneration policy and its underlying principles before they are adopted and the selection of identified staff.
- The Supervisory Board has an Audit and Risk Committee (ARC Committee) and as of the moment of the IPO the Selection, Appointment and Remuneration Committee was split in the Selection and Appointment Committee and the Remuneration Committee. These committees are composed of members of the Supervisory Board. The full Supervisory Board remains responsible for any decisions taken, even if they have been prepared by a committee.
- The duties, composition, expertise, independence and organization of the committees of the Supervisory Board are described in further detail in their rules of procedure, which are included in two appendices to the Rules of Procedure of the Supervisory Board.
- The Remuneration Committee provides the Supervisory Board with support and advice in relation to its duties and responsibilities regarding remuneration policy and remuneration practices. Decisions taken by the Supervisory Board in this area are prepared by the Remuneration Committee.
- Without prejudice to the duties of the Remuneration Committee, the ARC Committee examines whether the incentives created by the remuneration system take account of risk, capital, liquidity and the probability and staggering of profit forecasts, for the purpose of supporting the introduction of sound remuneration policy and practices. The ARC Committee also provides input for the selection of identified staff.
- The Executive Board has decision-making powers and responsibilities relating to the remuneration policy in respect of all employees, with the exception of the Executive Board itself and the Supervisory Board. The Executive Board also decides on the individual remuneration of senior managers (SMs, job levels 22-23).
- Control functions (also known as key functions) are departments that are responsible for the control and supervision of operations as well as the risks arising from those operations, and in doing so operate independently from the rest of the organization. They advise and support the Executive Board and Supervisory Board, and report directly to the Executive Board and Supervisory Board on compliance with applicable legislation and regulations and internal codes. Employees in control functions are defined as senior and/or managerial employees working in the compliance, audit, risk management and actuarial functions. The compliance, audit and risk management functions also play an active role in the context of the remuneration policies and practices relating to other groups of employees.
- The human resources function is very closely involved with the implementation of the remuneration policy. It also coordinates the preparation and evaluation of the remuneration policy and suggests what the policy should look like. In keeping with the control functions, the human resources function provides input for the ex-ante and ex-post risk adjustments of variable remuneration.
- The control functions and the human resources function collaborate actively on a regular basis. They share information and provide input for each other’s activities in the area of the remuneration policy.

Remuneration groups
Except where stated otherwise, the regulations contained in the remuneration policy apply to all employees who work under the responsibility of the Group. The specific groups mentioned are:
- Identified staff
- Employees in control functions (key functions)
- Policymakers
- Senior managers subject to the Dutch Financial Undertakings (Remuneration) Act (Wbfo)
- Executive directors and supervisory directors
- Senior and higher management
Key features of the remuneration system

Until 1 July 2014, the income of senior management, higher management and the CBA (Collective Bargaining Agreement) population (back-office and front-office) consisted of a fixed and a variable component. The Executive Board has received no variable remuneration since financial year 2011 based on Sections 1:128 and 1:129 of the Dutch Financial Supervision Act (Wft) and the corresponding transitional provisions. Following the collective bargaining negotiations with the trade unions, the variable remuneration for the CBA population was converted as of 1 July 2014 into a salary increase and a fixed supplement. The conversion was also implemented pro rata for a.s.r. as a whole, including higher and senior management. From 1 July 2014 onwards, the income of all salary groups including identified staff has consisted only of a fixed salary, with the exception of 115 front-office staff. This group has a fixed pay component and a target-related pay award of up to 20%.

Executive Board

The pay awarded to the members of the Executive Board comprises a fixed amount per month, including holiday allowance. The pay is indexed in accordance with the CBA for the insurance industry.

Other employees

The fixed pay awarded to employees consists of a fixed gross monthly salary, a fixed allowance (as a result of the conversion of variable pay for those employed at a.s.r. on 1 July 2014), 8% holiday allowance and a year-end bonus. The level of fixed pay depends on the weight attributed to an employee’s role, the related salary group and the employee’s general performance rating (assessment of deliverables and agreements on appropriate conduct). Fixed pay is adjusted for structural wage developments in accordance with the CBA for back-office positions in the insurance industry. The objectives pursued as part of how employees perform their duties are extrapolated from a.s.r.’s strategic targets. a.s.r.’s strategy is based on helping by taking action. This is reflected in KPIs relating to such issues as a customer dashboard, the Customer-Oriented Insurance Quality Mark and the Net Promoter Score. These KPIs form the basis of inspiring individual targets.

Identified staff

Variable remuneration awarded to identified staff before 1 July 2014 will be paid in instalments over the next few years. Identified staff are conditionally awarded a material share (i.e. 50%) of their variable pay in the form of cash and non-cash instruments. The conditional variable pay is deferred for three years; a reappraisal is performed at the end of the three-year period, after which the cash component is paid out. The non-cash component is subject to an additional retention period of two years. Some of the unconditional variable pay is paid out in cash immediately. The non-cash component of the unconditional variable pay is also retained for two years.

This group is also subject to a claw-back mechanism, a fairness clause and a penalty scheme, meaning that the Supervisory Board can claw back any variable pay already awarded if it was determined and awarded based on incorrect information.

In addition, the Supervisory Board has the right to adjust the level of the conditional variable pay if leaving the payment unchanged would go against the principles of reasonableness and fairness.

Top Income Act (WNT)

The WNT applies to (semi) public institutions. Within a.s.r. Group, this law imposes additional remuneration limits on WNT top officials of ASR Basis Ziektekostenverzekeringen N.V. and ASR Aanvullende Ziektekostenverzekeringen N.V. Within a.s.r., this specifically concerns the executive board and supervisory board of ASR Basis Ziektekostenverzekeringen N.V. Among others, these remuneration limits include a sectoral ceiling for fixed payment, a prohibition on variable payment and a maximum of severance payments.

a.s.r. annually accounts for the remunerations of the WNT top officials to the Ministry of VWS, after approval by the accountant.

Severance pay

No severance pay, either fixed or variable, may be awarded to an employee in the following cases:

- In the event that the employment relationship is terminated early at the employee’s own initiative, except where this is due to serious culpable conduct or neglect on the part of the company.
- In the event of serious culpable conduct or neglect in the performance of his or her role by the employee.
Additionally, the following conditions apply with respect to severance pay for policymakers.

- No severance pay is awarded in the event of the company’s failure.
- No severance pay that can be classified as variable is awarded to policymakers of a.s.r. or banks and insurers that are part of the Group.
- No fixed severance pay may be awarded to this group of employees unless this severance pay was agreed before 7 February 2015 (or before 20 June 2012 in the case of members of the a.s.r. Executive Board) or is agreed when the employee in question commenced his or her activities as a policy-maker after 7 February 2015.

**Pension**

The principal features of the pension scheme were as follows in 2016:

1. Average-pay pension plan;
2. Retirement age: 67 years;
3. Accrual rate for old-age pension: 1.875% for all salary groups;
4. Pensionable salary: fixed annual salary on 1 January of any year (capped at € 101,519 gross, this is offset by a contribution for the accrual of a net pay pension);
5. Partner’s pension: 70% of projected old-age pension;
6. Orphan’s pension: 14% of projected old-age pension;
7. Employee contribution: 6% of pensionable earnings;
8. Flexible elements: early retirement, deferred retirement, exchange, high/low, part-time;
9. a.s.r. does not allow for the award of discretionary pensions.

**Pre-pension allowance**

As a result of statutory pre-pension regulations, a.s.r. removed all pre-pension elements from its pension plans in 2006. Employees who joined a.s.r. before 1 January 2006 were initially compensated for this removal through optimization of their accrual rate and the state pension offset. Where such compensation was inadequate, the employees were awarded a pre-pension allowance, the amount of which varied based on their age and the original pension commitment. The pre-pension allowance for employees who joined a.s.r. after 1 January 2006 was 1% of their pensionable salary.

As a result of the change to the pension plan agreed with the Works Council, an additional pre-pension allowance was introduced with effect from 1 January 2015 for employees who had a pension accrual rate of 2.25% at year-end 2013. The supplementary pre-pension allowance has been set at 2.25%.

The allowance is paid until the end date of the (regular) pre-pension allowance, subject to a maximum of five years.

Once every three years, an independent consultancy is hired to perform a market comparison (remuneration benchmark). For the complete a.s.r. remuneration policy please see: asrnl.com.

**B.1.3 Related-party transactions**

Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

**B.1.4 Remuneration of Supervisory Board and Executive Board**

The remuneration policy of the Executive and Supervisory Board members is determined in accordance with the current Articles of Association of ASR Nederland N.V. Specific for health insurance companies, WNT (wet normering topinkomens) is applicable.

**B.1.4.1 Remuneration of Supervisory Board members**

The supervisory board of ASR Basis Ziektekostenverzekeringen N.V. is represented by the following members:

- C. van der Pol
- A.P. Aris
- J.P.M. Baeten
- M.H. Verwoest

The annual remuneration for the members of the Supervisory Board are accounted for in the remuneration paragraph of the annual report of ASR Nederland N.V.
B.1.4.2 Remuneration of current and former Executive Board members

The remuneration of current and former members is in accordance with the 2016 remuneration policy.

In accordance with the remuneration law "Wet aansprakelijkheidsbeperking DNB en AFM en bonusverbod staatsgesteunde ondernemingen", issued by the Dutch government, no variable remuneration has been disbursed to the executive members for the period as from the 2014 a.s.r. financial year until the current 2016 a.s.r. financial year.

The remuneration can be broken down as follows:

<table>
<thead>
<tr>
<th>Executive Board member 1</th>
<th>Fixed employee benefits 2</th>
<th>Short-term variable employee benefits 3</th>
<th>Post-employment benefits 4</th>
<th>Pension benefits 5</th>
<th>Expense allowance</th>
<th>Termination benefits</th>
<th>Long-term variable remuneration</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>drs. J.M. Hendriks RA *</td>
<td>152</td>
<td>-</td>
<td>-</td>
<td>36</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>188</td>
</tr>
<tr>
<td>drs. J.D. Lansberg **</td>
<td>69</td>
<td>-</td>
<td>-</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>81</td>
</tr>
<tr>
<td>P.H. van Holst-Wormser ***</td>
<td>58</td>
<td>-</td>
<td>-</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>70</td>
</tr>
<tr>
<td>Total</td>
<td>279</td>
<td>-</td>
<td>-</td>
<td>60</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>339</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Executive Board member 1</th>
<th>Fixed employee benefits 2</th>
<th>WNT maximum 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>drs. J.M. Hendriks RA *</td>
<td>152</td>
<td>231</td>
</tr>
<tr>
<td>drs. J.D. Lansberg **</td>
<td>69</td>
<td>77</td>
</tr>
<tr>
<td>P.H. van Holst-Wormser ***</td>
<td>58</td>
<td>57</td>
</tr>
<tr>
<td>Total</td>
<td>279</td>
<td>365</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Executive Board member 1</th>
<th>Fixed employee benefits 2</th>
<th>Short-term variable employee benefits 3</th>
<th>Post-employment benefits 4</th>
<th>Pension benefits 5</th>
<th>Expense allowance</th>
<th>Termination benefits</th>
<th>Long-term variable remuneration</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>drs. J.M. Hendriks RA *</td>
<td>110</td>
<td>-</td>
<td>-</td>
<td>26</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>136</td>
</tr>
<tr>
<td>P.H. van Holst-Wormser ***</td>
<td>243</td>
<td>-</td>
<td>-</td>
<td>41</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>284</td>
</tr>
<tr>
<td>H. Vlasblom ****</td>
<td>134</td>
<td>-</td>
<td>-</td>
<td>42</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>176</td>
</tr>
<tr>
<td>Total</td>
<td>487</td>
<td>-</td>
<td>-</td>
<td>109</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>596</td>
</tr>
</tbody>
</table>

1 This table is intended for top-level executives (and former top-level executives) with executive duties, i.e. the members of the highest executive body and their subordinates, and those tasked with the day-to-day management of the overall legal entity.

* Joined on 1 April 2015.

** Joined on 1 September 2016.

*** Term of service ended 31 March 2016.

**** Term of service ended 31 October 2015.

2 To determine the norm, the variable remuneration is attributed to the year in which it was awarded. The overview in the Appendix specifies the year of award and year of payment of the variable remuneration.

3 The norm is determined while disregarding the employer’s pension contribution.
Variable remuneration
Until 2014 P.H. van Holst-Wormser was granted variable remuneration. That variable remuneration is deferred and will be paid in tranches until 2020. The variable remuneration granted is provisioned for and recognized as a cost in the reporting period of the grant. Part of the deferred variable remuneration is dependent on the development of a.s.r., and its development and consequential final measurement is determined on the date of payment. Based on the present estimates the following amounts will be paid in tranches: 2017 € 34 thousand, 2018 € 21 thousand, 2019 € 14 thousand and € 2020 € 8 thousand.

B.2 Fit and proper requirements

This paragraph contains a description of group policy, which is applicable for the solo entity. The policy pursued by a.s.r. concerning fit and proper requirements for persons who effectively run the undertaking and other key functions contributes to a controlled and sound business operations and promotes the stability and integrity of a.s.r. as well as customer confidence.

The fit and proper requirements that are imposed on persons who effectively run the undertaking and other key functions are included in the job profile, which is used as a basis for recruitment. Each year, an assessment is made of the extent to which an employee requires training to perform its duties. In addition, a.s.r. has developed a training plan for the continuing education of persons who effectively run the undertaking and other key functions.

a.s.r. assesses all prospective employees for their reliability and integrity prior to their appointment.

B.3 Risk management system including the own risk and solvency assessment Risk Management System

This paragraph contains a description of group policy, which is applicable for the solo entity. It is of great importance that risks are timely and adequately controlled. In order to do so, a.s.r. has implemented a Risk Management framework based on internationally recognized and accepted standards (such as the COSO ERM framework and ISO 31000:2009 risk management principles and guidelines). With the aid of this framework, material risks that a.s.r. is, or can be, exposed to are identified, measured, managed, monitored and evaluated. The framework is both applicable to a.s.r. Group and the underlying business entities.

B.3.1 Enterprise Risk Management Framework

The framework below is the risk management framework as applied within a.s.r. The framework is based on the Enterprise Risk Management (ERM) model by COSO³.

---

\[ y = \frac{x \cdot a}{356} \] where: \( x \) = WNT remuneration cap applicable to institution, \( a \) = part-time factor (maximum 1.0 FTE) and \( b \) = term of service in calendar days.
Risk strategy (incl. risk appetite)
a.s.r.’s risk strategy aims to ensure that decisions are made within the boundaries of the risk appetite, as stipulated annually by the Executive Board and the Supervisory Board. The risk appetite is the level of risk that a.s.r. is prepared to take (see ‘Risk strategy and risk appetite’).

Risk governance
a.s.r. employs a risk governance framework that entails the tasks and responsibilities of the risk management organization and the structure of the Risk committee.

Systems and data
In order to report the correct figures and to apply risk-mitigating measures timely, it is of vital importance to have qualitatively adequate data and systems. To ensure this, a.s.r. had developed policies for data quality in line with Solvency II. Tools, models and systems are implemented to support the risk management process by giving guidance and insight in the key risk indicators, risk tolerance levels, boundaries and actions and remediation plans to mitigate risks.

Risk policies and procedures
The classification of risks within a.s.r. is performed in line with the Solvency II risks. Each risk category consists of a policy that explains how risks are identified, measured and controlled within a.s.r.

Risk culture
Risk culture is an important subject that emphasizes the human side of risk management. The Executive Board has a distinguished role in expressing the appropriate norms and values (tone at the top). a.s.r. employs several measures to increase the risk awareness and, in doing so, the risk culture.

Risk management process
The risk management process explains the central steps for the implementation of the risk strategy. Through five steps the risks within the company can be effectively managed. These steps include: 1) identify risks; 2) measure risks; 3) manage risks; 4) monitor and report on risks; and 5) evaluate the risk profile and risk management framework.

B.3.1.1 Risk strategy and risk appetite
The risk strategy of a.s.r. aims to ensure that management decisions lead to a risk profile that remains in line with the mission of the organization. The risk strategy entails all processes to manage identified risks and to take advantage of opportunities that come around. In order to achieve this, a risk appetite is established so that the risk profile can be managed within the boundaries as determined by the Executive Board and approved by the Supervisory Board. These risk boundaries are set with the goal of remaining a solid insurance company with the right balance between risk and return. The risk appetite describes the level of risk a.s.r. is prepared to take to realize the strategic goals. Risk exposures are actively managed to ensure that the risks will stay within the defined limits.

The risk appetite represents the level of risk a.s.r. is willing to take for the realization of its strategic goals, with a sound balance between risk and return. The risk appetite of ASR Basis Ziektekostenverzekeringen N.V. is derived from the group...
level risk appetite and covers both financial and non-financial risks. Risk tolerances, limits and targets are set for all risk appetite statements. Objectives of the risk appetite are:

- To serve as an important steering instrument on a daily basis: a pragmatic approach at both group-, legal entity- and business unit level. This helps to develop a vision with respect to risk, which is used in the day-to-day decision-making process;
- To link the risk appetite to the strategic pillars, in order to indicate a.s.r.’s willingness to take risks.

The risk appetite is based on a.s.r.’s mission, vision and strategy, determined by the Executive Board. The overall mission is to offer transparent insurance solutions as a trusted partner to customers, while creating sustainable and stable value for a.s.r.’s stakeholders. This mission is translated into the prioritization of simple and transparent products, clear communication and fair treatment of customers. The strategy is derived from the mission and is based on four pillars: fulfilling customer needs, pricing discipline and underwriting excellence, cost effectiveness and maintaining a cash generative business model. a.s.r. strives to execute these four strategic pillars within all of the business lines.

**Fulfilling Customer Needs**

a.s.r. aims to offer customers simple, transparent products that fulfil their needs.

**Excellence in Pricing, Underwriting and Claims Handling**

a.s.r. intends to maintain a disciplined pricing strategy focusing on further deepening its knowledge of customer behavior and continuing to enhance and further develop its experience and skills in respect of pricing and underwriting.

**Cost Effectiveness**

a.s.r. aims to continuously focus on effectively managing its costs.

**Cash Generative Business Model**

a.s.r.’s objective for the Group is to maintain its operation on a cash generative business model backed by a sound investment policy and investment mix to deliver robust, high-quality earnings underpinned by strong capital generation.

Through a top-down strategic risk analysis at group level and bottom-up control risk self assessments from the legal entities the most important strategic risks are identified. For each of these risks an estimation of the probability and impact is made to prioritize the risks. The outcomes of these analyses are input for defining the level of risk the organization is willing to take in order to achieve strategic goals. The risk appetite is formulated to provide steering and direction to the management of the strategic risks. The risk appetite contains a number of qualitative and quantitative risk statements. The statements point out the risk preferences and tolerances of the organization and are viewed as key elements for the realization of our strategy. With the use of hard and soft limits the boundaries for accepting risks are objective and evident. Soft limits are used as early warning signals to prevent risk taking beyond the hard limits. The performance against these statements is monitored in the risk committees. The statements and limits are evaluated regularly to maintain alignment with the strategy.

**B.3.1.2 Risk governance**

a.s.r.’s risk governance could be described by:

- risk ownership;
- the implemented three lines of defence model and associated (clear delimitation of) tasks and responsibilities; and
- the risk committee structure to ensure adequate strategic decision making

**Risk ownership**

The Executive Board has the final responsibility for risk exposures and management within the organization. Part of the responsibilities have been delegated to persons that manage the divisions where the actual risk-taking takes place. Risk owners are accountable for one or more risk exposures that are inextricably linked to the department they are responsible for. Through the risk committee structure, risk owners provide accountability on ‘their’ risk exposures.

**Three lines of defence**

The risk governance structure is based on the ‘three lines of defence’ model. The ‘three lines of defence’ model consists of three defence lines with different responsibilities with respect to the ownership of controlling risks. The model below provides insight in the organisation of the three lines of defence within a.s.r.
**Positioning of key functions**

Within the risk governance, the key functions (compliance, risk, actuarial and audit) are organised in accordance with Solvency II regulation and play an important role as countervailing power of management in the decision making process. The four key functions are independently positioned within a.s.r. The risk and actuarial function are positioned under responsibility of the CFO of the Group; the compliance and audit function under the responsibility of the CEO of the Group. All functions take place in the central risk committees. None of the functions has voting rights in the committees, in order to remain fully independent as countervailing power. All functions have direct communication lines with the Executive Board and can escalate to the chairman of the Audit and Risk Committee of the Supervisory Board.

**Group Risk Management**

Group Risk Management is responsible for the execution of the risk management function and the actuarial function. ASR Basis Ziektekostenverzekeringen N.V. uses the facilities of the Group. The department is led by the CRO. Group Risk Management consists of the following sub-departments:

- Enterprise Risk Management;
- Financial Risk Management.

**Enterprise Risk Management**

ERM is responsible for the second line strategic risk and operational (including IT) risk management and the enhancement of the risk awareness within the organisation. The responsibilities with regard to strategic risk management include the development of risk policies, the annual update of the risk strategy (risk appetite), the coordination of the Control Risk Self Assessment (CRSA) process, the monitoring of the non-financial risk profile and risk priorities of a.s.r. For the management of operational risks, a.s.r has a solid Risk-Control framework in place that contributes to its long-term solidity. The quality of our framework is continuously enhanced by the analysis of operational incidents and periodic assessments. Enterprise Risk Management actively promotes risk awareness at all levels to contribute to the vision of staying a socially relevant insurer.

**Financial Risk Management**

Financial Risk Management (FRM) is responsible for the second line market risk, counterparty risk, underwriting risk and liquidity risk management at a.s.r. and its legal entities. Other responsibilities are model validation and policies on valuation.
and risk. FRM is also responsible for the actuarial function. As part of the actuarial function, FRM reviews the technical provisions, monitors methodologies, assumptions and models used in these calculations, and assesses the adequacy and quality of data used in the calculations. Furthermore, the actuarial function monitors the profitability of new business and determines if risks related to the profitability of new products are sufficiently addressed in the product development process.

Compliance
Compliance is responsible for the execution of the compliance function. An important task of Compliance is to be the countervailing power to the Executive Board and management in managing compliance risks for a.s.r. and its subsidiaries. The mission of the compliance function is to enhance and ensure a controlled and sound business operations and to safeguard a.s.r.’s reputation.

As second line of defence, Compliance encourages the organization to comply with relevant rules and regulations, ethical standards and the internal standards derived from them (‘rules’) by providing advice and devising policy. Compliance supports the first line in the identification of compliance risks and assess the effectiveness of risk management on which Compliance reports to the relevant risk committees. In doing so, Compliance uses a compliance risk and monitoring framework. In line with risk management, Compliance also creates further awareness in order to promote a culture of integrity. Compliance coordinates contacts with regulators in order to maintain an effective relationship and keeps oversight of the current topics.

Audit
The Audit department, the third line of defence, provides an independent opinion on governance, risk and management processes, with the goal of supporting the Executive Board and the other management of a.s.r. in achieving the corporate objectives. To that end, Audit evaluates the effectiveness of governance, risk and management processes, and provides pragmatic advice that can be implemented to further optimize these processes. In addition, senior management can engage Audit for specific advisory projects.

Risk committee structure
a.s.r. has established a structure of risk committees with the objective to monitor the risk profile for a.s.r., its legal entities and its business lines in order to ensure that it remains within the risk appetite and the underlying risk tolerances and risk limits. When triggers are hit or likely to be hit, risk committees can decide to take measures and to increase the frequency of their meetings. For each of the risk committees a statute is drawn up in which the tasks, composition and responsibilities of the committee are defined.

The risk committee structure is as follows:
ASR Basis Ziektekostenverzekeringen N.V. uses the risk infrastructure of the Group (see below), but has its own business risk committee. Both operational and financial risk are in scope of this committee.
The Audit and Risk Committee was established by the Supervisory Board to gain support in the following matters:

- Assessment of the risk appetite proposal based on the financial and non-financial risk reports;
- Assessment of the annual report, including the financial statements;
- The relationship with the independent external auditor, including the assessment of the qualities and independence of the independent external auditor and the proposal by the Supervisory Board to the AGM to appoint the independent external auditor;
- The performance of the audit function, compliance function and the risk management function;
- Compliance with rules and regulations; and
- The financial position.

The Audit and Risk Committee has three members, one of whom acts as its chair.

The a.s.r. Risk Committee is a sub-committee of the Executive Board and monitors the overall risk profile on a quarterly basis. At least annually, the a.s.r. Risk Committee determines the risk appetite statements, limits and targets for a.s.r. and business lines. This relates to the overall a.s.r. risk appetite and the subdivision of risk appetite by financial and non-financial risks. The risk appetite is then submitted to the a.s.r. Audit and Risk Committee, which advises the Supervisory Board on the approval of the risk appetite. The a.s.r. Risk Committee also monitors the progress achieved in managing risks included in the Risk Priorities of the Executive Board.

All members of the Executive Board participate in the a.s.r. Risk Committee, which is chaired by the CEO of the Group. The involvement of the Executive Board ensures that risk decisions are being addressed at the appropriate level within the organization. In addition to the Executive Board, the CRO, Director of Audit and Director of Integrity are members of the Committee.
Non-Financial Risk Committee
The Non-Financial Risk Committee discusses, advises and decides upon non-financial risk policies. The most relevant risk policies are approved by the a.s.r. Risk Committee. The Non-Financial Risk Committee monitors that non-financial risks are adequately managed and monitors that the risk profile stays within the agreed risk limits.

Financial Risk Committee
The Financial Risk Committee discusses and decides upon financial risk policies. The most relevant risk policies are approved by the a.s.r. Risk Committee. The Financial Risk Committee monitors and controls financial risks (market, insurance, liquidity and counterparty default risk). The Financial Risk Committee also monitors whether the risk profile stays within the risk limits.

Capital, Liquidity and Funding Committee
As such, the Capital, Liquidity and Funding Committee prepares and assesses the technical analysis of capital, liquidity and funding positions, rating policy, rating model reporting, and treasury activities. The Chairman of the Capital, Liquidity and Funding Committee is the Director of Group Asset Management.

Model Validation Committee
The model validation committee is a subcommittee of the Financial Risk Committee and is responsible for the execution and update of the model validation policy and for the approval of existing or newly developed validated models before taken into use.

Business Risk Committees
The business lines manage and control their risk profile through the Business Risk Committees. The Business Risk Committees monitor that the risk profile of the business line stays within the risk appetite, limits and targets, as formulated by the Executive Board.

Central Investment Committee
This is not applicable for ASR Basis Ziektekostenverzekeringen N.V.

Product Approval and Review Committee
The Product Approval and Review Committee is responsible for the final decision-making process around the introduction of new products and adjustments in existing products. The committee evaluates if risks in newly developed products are sufficiently addressed. New products need to be developed in such a way that they are cost efficient, reliable, useful and secure.

B.3.1.3 Systems and data
Tools, models and systems are implemented to support the risk management process by giving guidance and insight in the key risk indicators, risk tolerance levels, boundaries and actions and remediation plans to mitigate risks. The availability, adequacy and quality of data and IT systems is important in order to ensure that correct figures are reported and risk mitigating measures can be taken in time. It is important to establish under which conditions the management information that is submitted to the risk committees has been prepared and which quality safeguards were applied in the process of creating this information. This allows the risk committees to ascertain whether the information is sufficient to base further decisions on. a.s.r. has a Data Governance and Quality policy in place to support the availability of sound management information. This policy is evaluated on an annual basis and revised at least every three years to keep the standards in line with the latest developments on information management. The quality of the information is reviewed on the basis of the following aspects, based on Solvency II:
- Completeness (including documentation of accuracy of results)
- Adequacy
- Reliability
- Timeliness

The integrity, i.e. reliability, of information is the degree to which it is up-to-date, complete and error-free. The preparatory body or department also checks the assumptions made and the plausibility of the results, and ensures coordination with relevant parties. When a preparatory body has established that the information is reliable and complete, it approves and formally submits the document(s) to a risk committee.
The information involved tends to be sensitive. To prevent unauthorized persons from accessing it, it is disseminated using a secure channel or protected files. a.s.r.’s information security policy contains guidelines in this respect.

The aim of the information security policy is to take measures to ensure that the requirements for the availability, reliability and confidential use of systems and data are met.

- Information availability refers to the degree to which the information is at hand as soon as the organization needs it, meaning, for instance, that the information should be retrievable on demand and that it can be consulted and used at the right time.
- Information reliability refers to the degree of the accuracy and completeness of computer-processed data, given the uses they are intended for.
- ‘Confidential use’ refers to the degree to which the information is available to authorized persons only and the degree to which it is not available to unauthorized persons.

There are technical solutions for accomplishing this, by enforcing a layered approach (defence-in-depth) of technical measures to avoid unauthorized persons (i.e. hackers) to compromise a.s.r. corporate data and systems. In this perspective, one may think of methods of logical access management, intrusion detection techniques, in combination with firewalls that are aimed at preventing hackers and other unauthorized persons from accessing information stored on a.s.r. systems. Nevertheless, confidential information can also have been committed to paper. In addition to technical measures the physical measures, such as the lock-down of a certain room, can also form part of the information security environment. a.s.r.’s information security policy is based on ISO 27002 ‘Code of practice for information security management’. This Code describes best practices for the implementation of information security.

B.3.1.4 Risk policies and procedures

a.s.r. has established policies for each of the main risk categories (market, counterparty default, liquidity, insurance, strategic and operational). These policies address the accountabilities and responsibilities for the management of the different risk types. Also the methodology for risk measurement is included in the policies. The content of the policies is aligned to create a consistent and complete set. The risk policy landscape is maintained by Group Risk Management and Compliance. These departments also monitor the correct implementation of the policies in the business. New risk policies or updates of existing risk policies, are approved by the risk committees as mentioned in the previous section.

B.3.1.5 Risk culture

Risk awareness is a vital component of building a sound risk culture within a.s.r. that emphasizes the human aspect in the management of risks. In addition to gaining sufficient knowledge, skills, capabilities and experience in risk management, it is of importance that an organization enables objective and transparent risk reporting in order to manage them more effectively.

The Executive Board of the Group clearly recognizes the importance of risk management and is therefore represented in all of the major group level risk committees. Risk Management is involved in the strategic decision-making process, where the company’s risk appetite is always considered. The awareness of risks during decision-making is continually addressed when making business decisions, for example by discussing and reviewing risk scenarios and the positive and/or negative impact of risks before finalizing decisions.

It is very important that this risk awareness trickles down to all parts of the organization, and therefore management actively encourages personnel to be aware of risks during their tasks and projects, in order to avoid risks or mitigate them when required. The execution of risk analyses is embedded in daily business in, for example, projects, product design and outsourcing.

In doing so, a.s.r. aims to create a solid risk culture in which ethical values, desired behaviors and understanding of risk in the entity are fully embedded. Integrity is of the utmost importance at a.s.r.: this is translated into a code of conduct and strict application policies for new and existing personnel, such as taking an oath or promise when entering the company, and the ‘fit and proper’ aspect of the Solvency II regulation, ensuring that a.s.r. is overseen and managed in a professional manner.

Furthermore, a.s.r. believes it is important that a culture is created in which risks can be discussed openly and where risks are not merely perceived to be negative: risks can also present a.s.r. with opportunities. Risk Management (both centralized and decentralized) is positioned as such, that it can communicate and report on risks independently and transparently, which also contributes to creating a proper risk culture.
B.3.1.6 Risk management process

The risk management process typically comprises of five important steps: 1) identifying; 2) measuring; 3) managing; 4) monitoring and reporting; and 5) evaluating. a.s.r. has defined a procedure for performing risk analyses and standards for specific assessments.

Identifying

Management endeavors to identify all possible risks that may impact the strategic objectives of a.s.r., ranging from the larger and/or more significant risks posed on the overall business, down to the smaller risks associated with individual projects or smaller business lines. Risk identification comprises of the process of identifying and describing risk sources, events, and the causes and effects of those events.

Measuring

After risks have been identified, quantitative and/or qualitative assessments of these risks take place to estimate the likelihood and impact associated with them. Methods applicable to the assessment of risks are:

- Sensitivity analysis;
- Stress testing;
- Scenario analysis;
- Expert judgments (regarding likelihood and impact); and
- Portfolio analysis.

Managing

Typically, there are five strategies to manage risk:

- **Accept**: risk acceptance means accepting that a risk might have consequences, without taking any further mitigating measures;
- **Avoid**: risk avoidance is the elimination of activities that cause the risk;
- **Transfer**: risk transference is transferring the impact of the risk to a third party;
- **Mitigate**: risk mitigation involves the mitigation of the risk likelihood and/or impact.
- **Exploit**: risk exploitation revolves around the maximization of the risk likelihood and/or increasing the impact if the risk does happen.

Risk management strategies are chosen in a way that ensures that a.s.r. remains within the risk appetite tolerance levels and limits.

Monitoring and reporting

The risk identification process is not a continuous exercise. Therefore, risk monitoring and reporting are required to capture changes in environments and conditions. This also means that risk management strategies could, or perhaps should, be adapted in accordance with risk appetite tolerance levels and limits.

Evaluating

The evaluation step is twofold. On the one hand, evaluation means risk exposures are evaluated against risk appetite tolerance levels and limits, taking (the effectiveness of) existing mitigation measures into account. The outcome of the evaluation could lead to a decision regarding further mitigating measures or changes in risk management strategies. On the other hand, the risk management framework (including the risk management processes) is evaluated by the risk management function, in order to continuously improve the effectiveness of the risk management framework as a whole.

B.3.2 a.s.r.’s risk categories

There are six main risk categories at a.s.r., these are: insurance risk, market risk, counterparty default risk, liquidity risk, operational risk and strategic risk.

---

5 Based on COSO ERM and ISO 31000:2009.
Insurance risk
Insurance risk is the risk that premium and/or investment income will not be sufficient to cover current or future payment obligations, owing to the application of inaccurate technical or other assumptions and principles when developing and pricing products. a.s.r. recognizes the following Insurance risks:
- Non-life insurance risk
- Life insurance risk
- Health

Market risk
Market risk is the risk of a change in value due to movements in market variables. The following market risks have been identified:
- Interest rate risk
- Equity risk
- Property risk
- Spread risk
- Currency risk
- Concentration risk/market concentration risk

Counterparty default risk
Counterparty default risk is the risk of losses due to the unexpected failure to pay or credit rating downgrade of counterparties and debtors. Counterparty default risk exists in respect of the following counterparties:
- Reinsurers
- Consumers
- Intermediaries
- Counterparties that offer cash facilities
- Counterparties with which derivatives contracts have been concluded

Liquidity risk
Liquidity risk is the risk that a.s.r. is not able to meet its financial obligations to policyholders and other creditors when they become due and payable, at a reasonable cost and in a timely manner.

Operational risk
Operational risk is the risk of losses caused by weak or failing internal procedures, weaknesses in the action taken by personnel, weaknesses in systems or because of external events. The following subcategories of operational risk are used:
- Compliance
- Business process
- Information technology
- Outsourcing
- Financial reporting

Strategic risk
Strategic risk is the risk that a.s.r. or its business lines fail to achieve the objectives owing to incorrect decision-making, incorrect implementation and/or an inadequate response to changes in the environment.

Such changes may arise in the following areas:
- Demographics
- Competitive conditions
- Technology
- Macroeconomic conditions
- Laws and regulations and ethical standards
- Stakeholders
- Group structure (for product lines only)

Strategic risk may arise due to a mismatch between two or more of the following components: the objectives (resulting from the strategy), the resources used to achieve the objectives, the quality of implementation, the economic climate and/or the market in which a.s.r. and/or its business lines operate.
B.4 Internal control system

This paragraph contains a description of group policy, which is applicable for the solo entity. Within a.s.r., internal control is defined as the processes, affected by the board of directors, senior management, and other personnel within the organization, implemented to obtain a reasonable level of certainty with regard to achieving the following objectives:

- High-level goals, aligned with and supporting the organization's mission
- Effective and efficient use of resources
- Reliability of operational and financial reporting
- Compliance with applicable laws regulations and ethical standards
- Safeguarding of company assets

B.4.1 Strategic and operational risk management

The system of internal control includes the management of risks at different levels in the organization, both operational (discussed in section C.5) and strategic. Internal control at an operational level centers around identifying and managing risks within the critical processes that pose a threat to the achievement of the business line's objectives. The use of controls helps to mitigate or even completely eliminate identified risks. This increases the business line's chances of achieving its objectives and demonstrates that it is in control. Business lines report on the effectiveness of their controls on a quarterly basis. The effectiveness of controls is important input for the sign off that each business line provides on the financial figures.

At a strategic level, the major risks are identified and assessed periodically with a control risk self-assessment. After the analysis a list of main risks is established and risk management actions are assigned. The progress of these actions are monitored in risk committee.

B.4.1.1 Strategic Risk Management

Strategic risk is defined as the risk that a.s.r. will not reach its strategic objectives, because risk considerations are not or incorrectly addressed in decision-making processes, incorrect implementation of decisions and/or failure to respond adequately to market developments. Strategic risk management aims to identify and manage the most significant risks that may impact a.s.r.'s strategic objectives. Subsequently, the aim is to identify and analyze the risk profile as a whole, including risk interdependencies. The ORSA process is designed to identify, measure, manage and evaluate those risks that are of strategic importance to a.s.r.:

Identifying

Through the ORSA process a Control Risk Self-Assessment (CRSA) is conducted annually to identify risks that have an impact on the achievement of the organization’s strategic objectives. The outcomes of the CRSA is translated into risk scenarios and a list of main risks.

Measuring

a.s.r. conducts an own risk and solvency assessment (ORSA) each year or more frequently if required by significant changes in a.s.r.’s risk profile. The ORSA is a tool for risk and capital management. Through the ORSA process, the likelihood and impact of the identified risks are assessed, by transposing the risks into scenarios, taking into account (the effectiveness of) risk mitigating measures and planned improvement actions. Information from other processes is used to gain additional insights into the likelihood and impact. One single risk scenario takes multiple risks into account. In this manner, the risk scenarios provide (further) insights into risk interdependencies. In these scenario’s the impact on the balance sheet, the solvency position and the income statement is simulated.

Managing

As part of the CRSA processes, the effectiveness of risk mitigating measures and planned improvement actions is assessed. This means risk management strategies are discussed, resulting in refined risk management strategies.

Monitoring and reporting

The output of the ORSA process is translated into day-to-day risk management and monitoring and reporting, both at group level and product line levels. At the level of the product lines, risks are discussed in the Business Risk Committee.

Evaluating
Insights regarding likelihood and impact are evaluated against solvency targets. Based on this evaluation, conclusions are formulated regarding the adequacy of solvency objectives at group and individual legal entity level.

B.4.2 Compliance function

B.4.2.1 Positioning and structure of compliance function
The compliance function is a centralized function and, together with Investigation, is part of the Integrity department. ASR Basis Ziektekostenverzekeringen N.V. uses the facilities of the Group. The Integrity department is headed by a director who is appointed as the a.s.r. Compliance Officer for both a.s.r. and the supervised entities. The compliance function is considered a key function. The CEO of ASR Nederland N.V. has the ultimate responsibility for the compliance function. The a.s.r. Compliance Officer is appointed, at the CEO's suggestion, by the a.s.r. Audit and Risk Committee, which is part of the Supervisory Board of ASR Nederland N.V. The proposal is submitted to the Supervisory Board of ASR Basis Ziektekostenverzekeringen N.V.

The a.s.r. Compliance Officer reports directly to the CEO ASR Nederland N.V. and the Management Board of ASR Basis Ziektekostenverzekeringen N.V. In addition, the a.s.r. Compliance Officer is formally required to report to the chairman of the a.s.r. Audit and Risk Committee to safeguard the independent position of the compliance function and enables it to operate autonomously. The a.s.r. Compliance Officer is entitled to escalate critical compliance matters to the highest organizational level or the Supervisory Board of ASR Nederland N.V.

B.4.2.2 Responsibilities and duties
The mission of the compliance function is to enhance and ensure a controlled and sound business operations and to safeguard a.s.r.'s reputation.

The compliance function, as part of the second line of defence, is responsible for:
- Encouraging compliance with relevant rules and regulations, ethical standards and the internal standards derived from them ('rules') by providing advice and devising policy.
- Monitoring compliance with rules. The compliance function prepares a detailed list and performs an assessment of the compliance risks and how they are managed, taking a.s.r.'s objectives and the rules as a basis. As part of this, it makes use of a compliance risk and monitoring framework.
- Managing compliance risks by developing adequate compliance risk management, including auditing and, if necessary, arrangements concerning management and actions to be taken.
- Raising a greater sense of awareness in order to promote a culture of integrity.
- Coordinating contacts with regulators in order to maintain effective relationships with them.

B.4.2.3 Compliance charter
The compliance charter sets out the responsibilities, duties and governance of the compliance function at ASR Nederland N.V. The a.s.r. Compliance Officer ensures that the charter is approved by the a.s.r. Risk Committee and the a.s.r. Audit and Risk Committee. The compliance charter was updated and approved in 2016.

B.4.2.4 Annual Compliance plan
Developments in rules, the management of high compliance risks and action plans provide the basis for the annual compliance plan and compliance’s monitoring activities. The annual compliance plan is discussed with the Management Board of ASR Basis Ziektekostenverzekeringen N.V and submitted to the Executive Board of ASR Nederland N.V. and the a.s.r. Audit and Risk Committee for approval.

B.4.2.5 Reporting
The compliance function reports quarterly on compliance matters and progress made on the relevant actions at Group level, supervised entity level and at division level. The quarterly report of ASR Basis Ziektekostenverzekeringen N.V. is discussed with the Management Board of ASR Basis Ziektekostenverzekeringen N.V. and scheduled in the Business Risk Committee.

The quarterly report at Group level and supervised entity level is presented to the a.s.r. Risk Committee, discussed with them and submitted to the a.s.r. Audit and Risk Committee. The report is also shared and discussed with DNB, AFM and external auditor.
B.5 Internal audit function

This paragraph contains a description of group policy, which is applicable for the solo entity. The Audit Department provides a professional and independent assessment of the governance, risk management and internal control processes with the aim of aiding management in achieving the company’s objectives. The Audit Department evaluates the effectiveness of governance, risk management and internal control processes, and gives practical advice on process optimization. This statement of duties has been set down in the Audit Charter for ASR Nederland N.V. and the legal entities. The Audit Department reports its findings to the Executive Board of ASR Nederland N.V., to the managing board of ASR Basis Ziektekostenverzekeringen N.V. (if relevant) and, by means of the quarterly management report, to the a.s.r. Audit and Risk Committee.

The Audit Department has an independent position within a.s.r., as set down in the Audit Charter. The supervisory board of ASR Nederland N.V. guarantees Audit and its employees an independent, impartial and autonomous position in order to execute the mission of Audit. The head of the Audit Department reports to the chairman of the Executive Board of ASR Nederland N.V. and has a reporting line to the chairman of the a.s.r. Audit and Risk Committee. The Chief Audit Executive is appointed by the a.s.r. Audit and Risk Committee. In order to maintain the independence and impartiality of the internal audit function, the audit function is not influenced by the Executive Board of ASR Nederland N.V. and the managing board of ASR Basis Ziektekostenverzekeringen N.V. in the execution of an audit and the evaluation of and reporting on audit outcomes. The audit function is not subjected to any inappropriate influence from any other function, including the key functions.

The persons carrying out the internal audit function do not assume any responsibility for any other (key) function. The Audit Department has periodic consultations with DNB to discuss the risk assessment, findings and audit plan. The department also takes the initiative to organize a ‘tripartite consultation’ with DNB and the independent external auditor at least once a year. In 2016, one tripartite consultation was held for ASR Basis Ziektekostenverzekeringen N.V..

The Audit Department sets up a yearly audit plan based upon an extensive risk assessment. The Audit Department’s risk assessment is performed in consultation with the independent external auditor. The audit plan is approved by the a.s.r. Audit and Risk Committee. At least once a year, the audit plan is evaluated and any changes to the plan must be approved by the a.s.r. Audit and Risk Committee.

All Audit officers took the oath for the financial sector and are subject to disciplinary proceedings. All Audit officers have committed themselves to the applicable code of conduct of a.s.r., follow the Code of Ethics of the Institute of Internal Auditors (IIA) and comply with the specific professional rules of the Netherlands Institute of Chartered Accountants (NBA) and the professional association for IT-auditors in the Netherlands (NOREA).

Audit applies the standards of the IIA, NBA and NOREA for the profession of internal auditing. Each year, Audit performs a self-assessment and an internal quality review and reports the results to the chairman of the board and to the members of the a.s.r. Audit and Risk Committee. In accordance with the standards of the IIA, an external quality review is performed every four years. During the last review in 2016, Audit was approved by the IIA and received the Institute’s quality certificate.

B.6 Actuarial function

This paragraph contains a description of group policy, which is applicable for the solo entity. The Actuarial Function (AF) is one of four key functions in a.s.r.’s system of governance.

The main tasks and responsibilities of the AF are to:
- coordinate the calculation of technical provisions;
- ensure the appropriateness of the methodologies, underlying models and the assumptions made in the calculation of technical provisions;
- assess the sufficiency and quality of the data used in the calculation of technical provisions;
- compare best estimates against experience;
- inform the administrative, management or supervisory body of the reliability and adequacy of the calculation of technical provisions;
- express an opinion on the overall underwriting policy;
- express an opinion on the adequacy of reinsurance arrangements; and
• contribute to the effective implementation of the risk management system

The AF is part of the second line of defence and operates independently of both the first line (responsible for determining the technical provisions, reinsurance and underwriting), as well as the other three key functions (internal audit, risk management and compliance).

The AF for both ASR Nederland N.V. and the insurance legal entities is operationally part of a.s.r. Group Risk Management. The AF is performed by persons who have profound knowledge of actuarial and financial mathematics, proportionate to the nature, scale and complexity of the risks present in a.s.r.’s businesses.

There are two function holders. One is responsible for the legal entities in the Life segment (Individual Life, Funeral and Pensions business lines) and the other for the entities in the Non-life segment (Property and Casualty, Disability and Health business lines). Both act as function holder for ASR Nederland N.V. The second-mentioned one acts as function holder for ASR Basis Ziektekostenverzekeringen N.V.

The AF function is represented in several risk committees. Each year, the AF drafts a formal report, which it discusses with the a.s.r. Risk Committee (or Executive Board) and the a.s.r. Audit and Risk Committee.

Independence of the AF is secured through several measures:
• The Actuarial function holders are nominated by the Chairman of the Board and appointed by the a.s.r. Audit and Risk Committee;
• The Actuarial function holders have unrestricted access to all relevant information necessary for the exercise of their function;
• The Actuarial function holders have a direct reporting line to the a.s.r. Risk Committee or Executive Board and the Audit and Risk Committee of a.s.r. The AF is free to report to one of the management or risk committees when considered necessary;
• The AF is free to report all relevant issues;
• In case of a conflict of interest with the CFO and/or CRO of the Group, the function holders may escalate directly to the CEO of the Group and to the Chairperson of the Audit and Risk Committee of a.s.r.;
• If the AF is asked to perform tasks that are outside the formal scope described in a charter, the function holder(s) assess if there is a conflict of interest. If so, the AF will not execute the task unless there are sufficient additional measures to mitigate conflicts of interest;
• The Internal Audit Department conducts an annual assessment of the functioning of the governance of a.s.r. and the (independent) operation of the Actuarial function;
• Target Setting and assessment of the function holders is done by the CFO of the Group and must be approved by the Chairman of the Audit and Risk Committee.

B.7 Outsourcing

This paragraph contains a description of group policy, which is applicable for the solo entity. a.s.r. has outsourced some of its operational activities. Despite this, a.s.r. remains fully responsible and accountable for these activities and the power of influence remains with a.s.r. To manage the risks related to outsourcing, a.s.r. has drafted a policy to safeguard a controlled and sound business operations.

Solid risk management, governance and monitoring are essential to manage outsourced activities. The outsourcing policy outlines the relevant procedures and is applicable to a.s.r. and its subsidiaries. A risk assessment must be performed for critical and/or important outsourced activities. This assessment focuses on e.g. concentration risk, competition risk, vendor lock-in and conflicts of interests.

To define the respective rights and obligations, a.s.r. drafts a written outsourcing contract with the service provider.

Confidentiality, quality of service and continuity are key for a.s.r. in carrying out its activities. In addition, customer centricity and compliance with law and regulations are essential, regardless of who performs the activities. To safeguard the quality of outsourced activities, service providers are closely scrutinized prior to selection and compliance with agreed obligations is
monitored. The findings of the monitoring activities serve as input for the periodic consultation on operational, tactical and strategic level with the service provider.

ASR Basis Ziektekostenverzekeringen N.V. has outsourced certain critical and/or important activities that are part of material operational processes. Outsourced activities are related to front- or back office activities In addition, the management and service of some supporting systems are also outsourced. IT is outsourced to DSW (IT infrastructure) and Multizorg (purchasing).

**B.8 Any other information**

Other material information about the system of governance does not apply.
C. Risk profile

Risk management is an integral part of our daily business activities. ASR Basis Ziektekostenverzekeringen N.V. applies an integrated approach in managing risks, ensuring that our strategic goals (customer interests, financial solidity and efficiency of processes) are maintained. This integrated approach ensures that value will be created by identifying the right balance between risk and return, while ensuring that obligations towards our stakeholders are met. Risk management supports ASR Basis Ziektekostenverzekeringen N.V. in the identification, measurement and management of risks and monitors to ensure adequate and immediate actions are taken in the event of changes in a.s.r.’s risk profile.

ASR Basis Ziektekostenverzekeringen N.V. is exposed to the following types of risks: market risk, counterparty default risk, liquidity risk, insurance risk (life), strategic risk and operational risk. A risk appetite is formulated and establishes a framework that supports the effective selection of risks.

The risk appetite specifies the maximum level of risk that the legal entity is willing to take in achieving its objectives. The risk appetite, which contains both financial and non-financial risk appetite statements, is recalibrated every year on the basis of the strategy of ASR Basis Ziektekostenverzekeringen N.V. The risk profile is reviewed and adopted by the Business Risk Committee every three months. This committee is made up of the managing board, members of the management team, members of the Finance and Risk column, the compliance officer, the risk manager and members of the Internal Audit Department. Risk appetite compliance reports are submitted to the central Non-Financial Risk Committee (NFRC) and the Financial Risk Committee (FRC). In the event of material variances, the controls that ASR Basis Ziektekostenverzekeringen N.V. must implement in order to bring the risk profile back within the bandwidths of the risk appetite are defined and documented. The risk appetite is thus an important operational instrument.

As of 1 January 2016 the Solvency II regime is in place. a.s.r. measures its risks based on the standard model as prescribed by the Solvency II regime and therefore the risk management framework and this chapter are fully aligned with Solvency II. The Solvency Capital Requirement (SCR) is determined as the change in own funds caused by a predetermined shock which is calibrated to a 1-in-200 year event. The basis for these calculations are the Solvency II technical provisions which are calculated as the sum of a best estimate and a risk margin.

Management of financial risks in 2016

ASR Basis Ziektekostenverzekeringen N.V. strives to find an optimal tradeoff between risk and return, also known as value based management. Value based management is applied in decision-making throughout the entire product cycle: from product approval to the payment of benefits and claims. At the more strategic level, decision-making takes place through balance sheet management. The FRC evaluates financial risk positions against the RAS on a monthly basis.

ASR Basis Ziektekostenverzekeringen N.V. assesses from time to time whether the technical provisions are sufficient to cover the insurance liabilities. To gain reasonable assurance regarding the accuracy of model outcomes in accordance with Solvency II, technical standards, model validation and other mitigating measures are applied. Primary scope of model validation are best estimate and solvency capital requirement models. These provisions were adequate at year-end 2016. The underlying assumptions for assessing the provision are adjusted from time to time to economic and non-economic developments.

Management of non-financial risks in 2016

Every year strategic risks are identified in a Control Risk Self-Assessment (CRSA). The CRSA is a method for the identification of risks that pose a threat to the achievement of the strategic and tactical objectives set out in the business plan. These risks are monitored on a quarterly basis. The risk priorities of ASR Basis Ziektekostenverzekeringen N.V. are defined based on the CRSA.

In 2016, a lot of attention was also devoted to the further embedding and optimization of the risk control framework. This risk control framework comprises a description of the principal risks and control measures in the processes. The internal control structure of ASR Basis Ziektekostenverzekeringen N.V. made an important shift to an even more risk-based focus, which was also incorporated in the revised Risk Management Policy. This allows for a stronger alignment between the risk appetite and the focus on risk, which in turn contributes to the extent to which risks remain within the predetermined risk appetite. In line with this, reporting systems were revised and improved, with the changes taking effect in 2017.
Extensive attention was given to providing insights into data quality. Several activities focusing on data quality were started, using a framework for norms and standards. Further steps were taken throughout 2016, and will continue to be taken in 2017, to support the reasonable assurance given by the actuarial function on the reliability of the financial statements.

**Key risk developments in 2016**

The Own Risk and Solvency Assessment (ORSA), which forms part of the Solvency II rules, is performed on an annual basis. The ORSA makes it possible to form a judgement on the position of ASR Basis Ziektekostenverzekeringen N.V. in terms of risk, solvency and capital, both now and in the future, under different stress scenarios and relative to the risk appetite. The ORSA provides insight into the robustness of the solvency position and the measures to be taken in diverse scenarios. The ORSA process is facilitated from the Group Risk Management Department. Representatives from ASR Basis Ziektekostenverzekeringen N.V. take part in the risk assessment sessions, the CRSA, and identify the principal risks. The next step involves drawing up scenarios in which the company’s ability to continue as a going concern could be jeopardized.

The solvency impact of several stress scenarios were calculated as part of the ORSA. Based on these scenarios, the Managing Board of ASR Basis Ziektekostenverzekeringen N.V. has defined mitigating measures that can be taken to continue meeting the solvency requirements in the event of the occurrence of a specific scenario. The ORSA process led to the identification of the following principal risks for ASR Basis Ziektekostenverzekeringen N.V.:

**Increasing legislative and regulatory burden**

Insurers are confronted with a structural proliferation of laws and regulations. The regulator is exerting increasing pressure and displaying a growing appetite for enforcement. As a result of this mounting regulatory pressure, there is a risk that:

- the reputation will be put under pressure if new requirements are not met in time;
- available resources will mostly be utilized in the cause of aligning the organization to new legislation, meaning there are fewer resources to spend on the core customer processes;
- processes will become less efficient and pressure on the workforce will increase;
- the regulator issues a direction or imposes a penalty for failing to achieve timely regulatory compliance.

**Insufficient procurement power**

ASR Basis Ziektekostenverzekeringen N.V. is a relatively small health insurer. Due to its limited size, there is the risk that ASR Basis Ziektekostenverzekeringen N.V. contracts healthcare at suboptimal conditions than the competition. The company may seek to increase its procurement power through partnerships with other health insurers.

**Own funds**

The capital management section describes the capital targets related to the risk appetite statements and dividend payments. The table below shows how the eligible funds of ASR Basis Ziektekostenverzekeringen N.V. relate to the different capital targets.

**Market value own funds under Solvency II**

*The amount under RAS is the minimal free surplus (€18,232 thousand), such that the RAS is met. The additional required capital relative to the RAS is stated below the lower limit target.*
Capital requirement
The required capital stood at €91,158 thousand per 31 December 2016. The required capital (before diversification) consists for €9,031 thousand out of market risk and the insurance risk amounted to €69,723 thousand as per 31 December 2016. 2015 figures are not presented here, as Solvency II replaced Solvency I as at 1 January 2016, which makes a comparison of these two years not useful.

SCR sensitivities
Also for sensitivities 2015 figures are not presented here, as Solvency II replaced Solvency I as at 1 January 2016, which makes a comparison of these two years not useful.

The sensitivities of the solvency ratio as at 31 December 2016, expressed as the impact on the ASR Basis Ziektekostenverzekeringen N.V. solvency ratio (in percentage points) are as presented in the table below. The total impact is split between the impact on the solvency ratio related to movement in the available capital and the required capital.

<table>
<thead>
<tr>
<th>Type of risk (%-points)</th>
<th>Available capital</th>
<th>Required capital</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>UFR -1%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Interest rate +1% (incl. UFR 4.2%)</td>
<td>-1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Interest rate -1% (incl. UFR 4.2%)</td>
<td>+1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Volatility Adjustment -10bp</td>
<td>-1</td>
<td>+1</td>
<td>-</td>
</tr>
<tr>
<td>Equity prices -20%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Property values -10%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Spread +75bps/VA +21bps</td>
<td>-3</td>
<td>-</td>
<td>-3</td>
</tr>
</tbody>
</table>

Risk | Scenario                                                                                         |
-----|-----------------------------------------------------------------------------------------------|
Interest rate risk – UFR | Measured as the impact of a lower UFR. For the valuation of liabilities, the extrapolation to the UFR of 3.2% after the last liquid point of 20 years remained unchanged. |
Interest rate risk (incl. UFR 4.2%) | Measured as the impact of a parallel 1% upward and downward movement of the interest rates. For the liabilities, the extrapolation to the UFR of 4.2% after the last liquid point of 20 years remained unchanged. |
Volatility Adjustment | Measured as the impact of a 10 bps decrease in the Volatility Adjustment. |
Equity risk | Measured as the impact of a 20% downward movement in equity prices. |
Property risk | Measured as the impact of a 10% downward movement in the market value of real estate. |
Spread risk (including impact of spread movement on VA) | Measured as the impact of an increase of spread on loans and corporate bonds of 75 bps. At the same time, it is assumed that the Volatility Adjustment will increase by 21 bps. |

Recently, EIOPA announced its decision on the Ultimate Forward Rate (UFR). The UFR will decrease from 2018 from 4.2% to 3.65% with steps of 15 basis points per year. In 2018 the UFR will be 4.05%. After the decline of the URF by 15 basis points the solvency ratio will remain above internal solvency objectives.

Expected development UFR
European Insurance and Occupational Pensions Authority (EIOPA) may reduce the ultimate forward rate used to extrapolate insurers’ discount curves to better reflect expected inflation and real interest rates. There are various scenarios regarding lowering the Ultimate Forward Rate (UFR) in 2017 and beyond, based on the proposed methodology as described in EIOPA’s consultation paper on the UFR. In the latest proposal, the UFR decreases to 3.7%, phasing in by 20 basis points per year. The impact on the solvency ratio of various UFR levels is stated below.
Interest rate sensitivity of solvency ratio
The impact of the interest rate on the solvency ratio, including the UFR effect, is stated below. The UFR methodology has been applied to the shocked interest rate curve.

Spread risk
The total fair market value of the fixed-income portfolio increased over the first half of 2016, resulting in a higher spread risk. The increase in of the fixed-income portfolio is mainly due to (i) the fall in interest rates (the portfolio has many long-duration instruments) and (ii) portfolio expansion due to de-risking.

In case of a scenario in which the average spread rises by 75 bps and the Volatility Adjustment (VA) rises by 21 bps, the solvency ratio decreases -3%. As the VA is used in the calculation of the liabilities and spread movement only has an impact on the credit portfolio, the impact of the VA increase is bigger than the impact of the spread increase. Therefore, the solvency ratio rises in the event of an increase in the average spread.

Loss absorbing capacity deferred tax
ASR Basis Ziektekostenverzekeringen N.V. uses the following methodology for the calculation of the Loss Absorbing Capacity Deferred Tax (LAC DT) benefit in euros. Below an overview of the components of the methodology for the calculation is presented:
<table>
<thead>
<tr>
<th>Component</th>
<th>Applicable?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Component 1 – Taxable profit (t)</td>
<td>✓</td>
</tr>
<tr>
<td>Component 2 – Taxable profit (t-1)</td>
<td>✓</td>
</tr>
<tr>
<td>Component 3 – NET DTA position</td>
<td>✓</td>
</tr>
<tr>
<td>Component 4 – Future taxable profit</td>
<td>✗</td>
</tr>
</tbody>
</table>

1. The unrounded LAC DT factor is determined based on component 1 - 3 only and will be compared with the buckets as defined by a.s.r. This means that the LAC DT factors only can be expressed as a multiple of 25% of the fictive fiscal loss (0%). The outcomes are rounded down. This bucket system ensures financial stability in the LAC DT benefit for a.s.r. Group in euros, resulting in financial stability of the solvency position of the Group.

2. The rounded LAC DT factors for all entities will be compared with a code of conduct. This code of conduct will be used to include potential risks not yet included in the model. In this way no increase will be realized in case a decrease in the next quarter is expected. The advised LAC DT factors result.

3. The advised LAC DT factors are reviewed by the 2nd line.

4. A proposal with the advised LAC DT factors will be presented to the Financial Risk Committee. The LAC DT factors to be used result.

**C.1 Insurance risk**

Insurance risk is the risk that future insurance claims and benefits cannot be covered by premium and/or investment income, or that insurance liabilities are not sufficient, because future expenses, claims and benefits differ from the assumptions used in determining the best estimate liability. The healthcare sector is part of the non-life portfolio.

The solvency buffer is held by ASR Basis Ziektekostenverzekeringen N.V. to cover the risk that claims may exceed the available insurance provisions and to ensure its solidity. The solvency position of ASR Basis Ziektekostenverzekeringen N.V. is determined and continuously monitored in order to assess if ASR Basis Ziektekostenverzekeringen N.V. meets the regulatory requirements.

As of 1 January 2016 the Solvency II regime is in place. ASR Basis Ziektekostenverzekeringen N.V. measures its risks based on the standard model as prescribed by the Solvency II regime. The Solvency Capital Requirement for each insurance risk is determined as the change in own funds caused by a predetermined shock which is calibrated to a 1-in-200 year event. The basis for these calculations are the Solvency II technical provisions which are calculated as the sum of a best estimate and a risk margin.

The insurance risk arising from the health insurance portfolio of ASR Basis Ziektekostenverzekeringen N.V. is as follows.

<table>
<thead>
<tr>
<th>Insurance risk - required capital</th>
<th>31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health insurance risk</td>
<td>69,723</td>
</tr>
</tbody>
</table>

**C.1.1 Health Insurance risk**

The Health insurance portfolio of ASR Basis Ziektekostenverzekeringen N.V. contains the following insurance risks:

- **NSLT Health risk**
  - This risk is applicable to the NSLT Health portfolio. The calculation is factor-based. The risk is calculated similarly to the Non-Life insurance risk
- **Health Catastrophe risk**
  - The calculation of this risk is scenario-based
NSLT Health Risk

Premium and reserve risk
The premium risk is the risk that the premium is not adequate for the underwritten risk. The premium risk is calculated over the maximum of the expected written premium of the next year, and the written premium of the current year.

Reserve risk is the risk that the current reserves are insufficient to cover the claims over a 12 month time horizon.

NSLT lapse risk
The basic health insurance is a compulsory insurance contract for one year without intermediate possibility of termination and therefore lapse risk is negligible for the basic health insurance.

Health catastrophe risk

Medical Expense
A health catastrophe for NSLT Health portfolio is an unexpected future event with a duration of one year. The risk is determined ultimo year. The amount of catastrophe risk is apparent from the number of insured and parameters for mass accident scenario and pandemic scenario that have been approved by Dutch Central Bank in consultation with Health Insurers Netherlands. Accident concentration is not applicable for NSLT Health. The catastrophe risk has a projection of one year (T) following from the contract boundary of one year in accordance with the Dutch Health Insurance Act for Health Insurance. After year T the risk is ‘zero’.

<table>
<thead>
<tr>
<th>Health insurance risk - required capital</th>
<th>31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health SLT</td>
<td></td>
</tr>
<tr>
<td>Health Non-SLT</td>
<td>69,044</td>
</tr>
<tr>
<td>Catastrophe Risk (subtotal)</td>
<td>2,542</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-1,863</td>
</tr>
<tr>
<td><strong>Health (Total)</strong></td>
<td><strong>69,723</strong></td>
</tr>
<tr>
<td>Medical expenses insurance and proportional reinsurance</td>
<td>69,044</td>
</tr>
<tr>
<td>Income protection insurance and proportional reinsurance</td>
<td>-</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Health Non-SLT (subtotal)</strong></td>
<td><strong>69,044</strong></td>
</tr>
<tr>
<td>Mass accident risk</td>
<td>184</td>
</tr>
<tr>
<td>Accident concentration risk</td>
<td>-</td>
</tr>
<tr>
<td>Pandemic risk</td>
<td>2,535</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-177</td>
</tr>
<tr>
<td><strong>Catastrophe risk (subtotal)</strong></td>
<td><strong>2,542</strong></td>
</tr>
</tbody>
</table>

For the NSLT Health portfolio, the provision at year-end 2016 can be broken down as follows under solvency:

<table>
<thead>
<tr>
<th>Segment</th>
<th>Solvency II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Similar to Non-Life techniques - Solvency II technical provision</td>
<td>31 December 2016</td>
</tr>
<tr>
<td>Best estimate</td>
<td>246,868</td>
</tr>
<tr>
<td>Risk margin</td>
<td>8,210</td>
</tr>
<tr>
<td><strong>Technical provision</strong></td>
<td><strong>255,078</strong></td>
</tr>
</tbody>
</table>
C.1.2 Managing health insurance risk

Health insurance risk is managed by monitoring claims frequency, the size of claims, inflation, handling time, benefit and claims handling costs. Concentration risk also qualifies as an insurance risk.

Claims frequency, size of claim and inflation
To mitigate the risk of claims, ASR Basis Ziektekostenverzekeringen N.V. bases its underwriting policy on claims history and risk models. The policy is applied to each client segment and to each type of activity. In order to limit claims and/or ensure that prices are adjusted correctly, the product line health NSLT also uses knowledge or expectations with respect to future trends to estimate the frequency, size and inflation of claims.

Handling time
The handling time for health care claims is mainly very short and the settlement is quick. Normally, within five days a claim is settled.

Benefit and claims handling costs
Taking estimated future inflation into account, benefit and claims handling costs are managed on the basis of regular reviews and related actions.

Concentration risk
Geographically, the risk exposure of ASR Basis Ziektekostenverzekeringen N.V. on its health portfolio is almost entirely concentrated in the Netherlands.

C.2 Market risk

Market risk is the risk of potential losses due to adverse movements in financial market variables. Exposure to market risk is measured by the impact of movements in financial variables such as equity prices, interest rates and property prices. The various types of market risk which are discussed in this section, are:

- interest rate risk
- equity risk
- property risk
- currency risk
- spread risk
- concentration risk

Market risk reports are submitted to the FRC at least once a month. Key reports on market risk include the Solvency II and economic capital report, the interest rate risk report and the report on risk budgets related to the strategic asset mix.

A summary of sensitivities to market risks for the regulatory solvency, total equity and profit for the year is presented in the tables below.

<table>
<thead>
<tr>
<th>Market risk - required capital</th>
<th>31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest rate</td>
<td>688</td>
</tr>
<tr>
<td>Equity</td>
<td>74</td>
</tr>
<tr>
<td>Property</td>
<td>-</td>
</tr>
<tr>
<td>Currency</td>
<td>138</td>
</tr>
<tr>
<td>Spread</td>
<td>8,907</td>
</tr>
<tr>
<td>Concentration</td>
<td>254</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-1,030</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>9,031</strong></td>
</tr>
</tbody>
</table>
The main market risks of ASR Basis Ziektekostenverzekeringen N.V. is spread risk. This is in line with the risk budgets based on the strategic asset allocation study.

The value of investment funds at year-end 2016 was €6,037 thousand. ASR Basis Ziektekostenverzekeringen N.V. applies the look-through approach for investment funds to assess the market risk.

The interest rate risk is the maximum loss of (i) an upward shock or (ii) a downward shock of the yield curve. For ASR Basis Ziektekostenverzekeringen N.V. the upward shock is dominant.

ASR Basis Ziektekostenverzekeringen N.V. applies the transitional measure for equity risk for shares in portfolio at 31 December 2015. The SCR equity shock was 22% at 31 December 2015 and linear, increasing to (i) 39% + equity dampener for type I shares and (ii) 49% + equity dampener for type II shares. The equity dampener has a value between -10% and 10%. In the event of increasing equity prices, the equity dampener will have a smaller dampening effect.

The diversification effect shows the effect of having a diversified investment portfolio.

### C.2.1 Interest rate risk

Interest rate risk is the risk that the value of assets, liabilities or financial instruments will change due to fluctuations in interest rates.

The required capital for interest rate risk is determined by calculating the impact on the available capital due to changes in the yield curve. Both assets and liabilities are taken into account. The interest rate risk is the maximum loss of (i) an upward shock or (ii) a downward shock of the yield curve according to the prescribed methodology. ASR Basis Ziektekostenverzekeringen N.V. applies a look-through approach for investment funds to assess the interest rate risk.

<table>
<thead>
<tr>
<th>31 December 2016</th>
<th>SCR interest rate risk up</th>
<th>-688</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCR interest rate risk down</td>
<td>40</td>
<td></td>
</tr>
</tbody>
</table>

| SCR interest rate risk | 688 |

ASR Basis Ziektekostenverzekeringen N.V. has assessed various scenarios to determine the sensitivity to interest rate risk. The impact on the solvency ratio is calculated by determining the difference in the change in available and required capital.

<table>
<thead>
<tr>
<th>31 December 2016</th>
<th>Effect on: Available capital</th>
<th>Required capital</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>UFR -1%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Interest rate +1% (incl. UFR 4.2%)</td>
<td>-1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Interest rate -1% (incl. UFR 4.2%)</td>
<td>+1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Volatility Adjustment -10bp</td>
<td>-1</td>
<td>+1</td>
<td>-</td>
</tr>
</tbody>
</table>

Interest rate risk is managed by aligning fixed-income investments to the profile of the liabilities.

An interest rate risk policy is in place for the Group as well as for the registered insurance companies. All interest rate-sensitive balance sheet items are in scope, including the employee benefit obligations of the Group. In principle, the sensitivity of the solvency ratio to interest rates is minimized. In addition, the exposure to interest rate risk for various term buckets is subject to maximum amounts.

### C.2.2 Equity risk

Equity risk is not applicable for ASR Basis Ziektekostenverzekeringen N.V.
C.2.3 Property risk

Property risk is not applicable for ASR Basis Ziektekostenverzekeringen N.V.

C.2.4 Currency risk

Currency risk measures the impact of losses related to changes in currency exchange rates. The table below provides an overview of the largest currency exposures in the portfolio.

The required capital for currency risk is determined by calculating the impact on the available capital due to a change in exchange rates. Both assets and liabilities are taken into account. For each currency, the maximum loss due to an upward and a downward shock of 25% is determined, where lower shocks are applied to several currencies (Danish crown; Bulgarian lev). For SCR currency risk, the look-through approach is applied for investment funds.

<table>
<thead>
<tr>
<th>Specification currencies with largest exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>The foreign currency position is monitored on a quarterly basis. The total net exposure in foreign currency is €4,415 thousand. The largest net-exposure is in USD, which mainly consists investment in bonds. The following tables show the currencies with the largest exposures:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>31 December 2015 - in €</th>
<th>Total</th>
<th>USD</th>
<th>GBP</th>
<th>CHF</th>
<th>AUD</th>
<th>HKD</th>
<th>ZAR</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td>4,415</td>
<td>4,156</td>
<td>258</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Net exposure</strong></td>
<td>4,415</td>
<td>4,156</td>
<td>258</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
</tbody>
</table>

C.2.5 Spread risk

Spread risk arises from the sensitivity of the value of assets and liabilities to changes in the level of credit spreads on the relevant risk-free interest rates. ASR Basis Ziektekosten N.V. has a policy of maintaining a well-diversified high-quality investment grade portfolio while avoiding large risk concentrations. Going forward, the volatility in spreads will continue to have possible short-term effects on the market value of the fixed income portfolio. In the long run, the credit spreads are expected to be realized and to contribute to the growth of the own funds.

The required capital for spread risk is determined by calculating the impact on the available capital due to the volatility of credit spreads over the term structure of the risk-free rate. The required capital for spread risk is equal to the sum of the capital requirements for bonds, structured products and credit derivatives. The capital requirement depends on (i) the market value, (ii) the modified duration and (iii) the credit quality category.

<table>
<thead>
<tr>
<th>31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCR spread risk - required capital</td>
</tr>
</tbody>
</table>

The sensitivity to spread risk is measured as the impact of an increase of spread on loans and corporate bonds of 75 bps. At the same time, it is assumed that the Volatility Adjustment which is applied to the liabilities will increase by 21 bps.

<table>
<thead>
<tr>
<th>31 December 2016</th>
<th>Effect on:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scenario</strong></td>
<td><strong>Available capital</strong></td>
</tr>
<tr>
<td>Spread +75bps/VA +21bps</td>
<td>-3</td>
</tr>
</tbody>
</table>
Composition of fixed income portfolio

Spread risk is managed on a portfolio basis within limits and risk budgets established by the relevant risk committees. Where relevant, credit ratings provided by the external rating agencies are used to determine risk budgets and monitor limits. A limited number of fixed-income investments do not have an external rating. These investments are generally assigned an internal rating. Internal ratings are based on methodologies and rating classifications similar to those used by external agencies. The following tables provide a detailed breakdown of fixed-income exposure by rating class, sector, and country of risk and level of subordination for the financial sector.

Assets in scope of spread risk are, by definition, not in scope of counterparty default risk. The tables include all bond, fixed income funds, preference shares and loans subject to spread risk according to our risk models.

<table>
<thead>
<tr>
<th>Rating Class</th>
<th>Exposure</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAA</td>
<td>57,830</td>
<td>21%</td>
</tr>
<tr>
<td>AA</td>
<td>70,688</td>
<td>26%</td>
</tr>
<tr>
<td>A</td>
<td>77,209</td>
<td>29%</td>
</tr>
<tr>
<td>BBB</td>
<td>56,749</td>
<td>21%</td>
</tr>
<tr>
<td>Lower than BBB</td>
<td>818</td>
<td>0%</td>
</tr>
<tr>
<td>Not rated</td>
<td>6,037</td>
<td>2%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>269,331</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>

ASR Basis Ziektekostenverzekeringen N.V. invests mainly in bonds with a rating of at least BBB.

<table>
<thead>
<tr>
<th>Sector</th>
<th>Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Governments</td>
<td>93,653</td>
</tr>
<tr>
<td>Financials</td>
<td>97,009</td>
</tr>
<tr>
<td>Corporates</td>
<td>75,319</td>
</tr>
<tr>
<td>Structured Instruments</td>
<td>3,350</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>269,331</strong></td>
</tr>
</tbody>
</table>

ASR Basis Ziektekostenverzekeringen N.V. holds a well-diversified portfolio of government bonds, corporate bonds and financials.

<table>
<thead>
<tr>
<th>Country</th>
<th>Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Netherlands</td>
<td>7,414</td>
</tr>
<tr>
<td>Germany</td>
<td>26,536</td>
</tr>
<tr>
<td>Austria</td>
<td>7,715</td>
</tr>
<tr>
<td>Belgium</td>
<td>17,684</td>
</tr>
<tr>
<td>France</td>
<td>8,281</td>
</tr>
<tr>
<td>Supranationals</td>
<td>8,476</td>
</tr>
<tr>
<td>Periphery</td>
<td>13,154</td>
</tr>
<tr>
<td>Other</td>
<td>4,393</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>93,653</strong></td>
</tr>
</tbody>
</table>

The largest government bond exposure of a.s.r. ASR Basis Ziektekostenverzekeringen N.V. is in German bonds.
### Financial institutions

<table>
<thead>
<tr>
<th></th>
<th>31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Senior</td>
<td>57,110</td>
</tr>
<tr>
<td>Tier 1</td>
<td>1,414</td>
</tr>
<tr>
<td>Tier 2</td>
<td>21,772</td>
</tr>
<tr>
<td>Tier 3</td>
<td>-</td>
</tr>
<tr>
<td>Covered</td>
<td>16,713</td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>97,009</strong></td>
</tr>
</tbody>
</table>

ASR Basis Ziektekostenverzekeringen N.V. does not invest in new Tier 1 financial bonds, redemptions therefore lead to the decrease in the Tier 1 portfolio.

The table above shows the exposure of the corporate bonds to sectors.

### Structured financial instruments

<table>
<thead>
<tr>
<th></th>
<th>31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABS</td>
<td>-</td>
</tr>
<tr>
<td>CDO</td>
<td>818</td>
</tr>
<tr>
<td>MBS</td>
<td>2,532</td>
</tr>
<tr>
<td>Structured financial instruments</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>3,350</strong></td>
</tr>
</tbody>
</table>

Redemptions are responsible for the decrease in the market value of the Structured Entities and occurred mainly in the MBS portfolios. The revaluations on the structured products portfolio decreased slightly in the course of 2016.

As ASR Ziektekosten Basis N.V. participates in structured entities solely for investment purposes, no other commitments or guarantees have been made to the entities concerned. The maximum exposure is therefore limited to the fair value of the structured entity and amounts to €3,350 thousand.

**Asset-backed securities (ABSs)**

There are currently no holdings in asset-backed securities.

**Collateralized debt obligation (CDO)**

CDOs are securities backed by a pool of bonds, loans or other assets. CDOs do not specialize in one type of debt, but are often non-mortgage loans or bonds. CDOs are unique in that they represent different types of debt and counterparty default risk. In the case of CDOs, these different types of debt are often referred to as ‘tranches’ or ‘slices’. Each slice has a different maturity and risk associated with it. The CDO is backed by a portfolio of European ABS.
Mortgage-backed securities (MBSs)
MBSs are a type of asset-backed security that is secured by a portfolio of mortgages. The MBS portfolio consists of AAA tranches in Dutch residential mortgage-backed securities.

Other structured financial instruments (SFI)
This part of the portfolio consists of equity tranches of CDOs, i.e. the most high-risk tranche in the CDO structure. These first-loss tranches will be the first to fall in value if losses occur in the assets that back the CDO and are not rated.

The following tables give a detailed overview of the distribution of the total fixed income portfolio over ratings and sectors.

<table>
<thead>
<tr>
<th>Ratings</th>
<th>Governance 31 December 2016</th>
<th>Financial institutions 31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAA</td>
<td>40,588</td>
<td>14,710</td>
</tr>
<tr>
<td>AA</td>
<td>37,936</td>
<td>23,980</td>
</tr>
<tr>
<td>A</td>
<td>4,239</td>
<td>33,912</td>
</tr>
<tr>
<td>BBB</td>
<td>10,890</td>
<td>24,407</td>
</tr>
<tr>
<td>Lower than BBB</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Not rated</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>93,653</strong></td>
<td><strong>97,009</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ratings</th>
<th>Corporates 31 December 2016</th>
<th>Structured entities 31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAA</td>
<td>-</td>
<td>2,532</td>
</tr>
<tr>
<td>AA</td>
<td>8,772</td>
<td>-</td>
</tr>
<tr>
<td>A</td>
<td>39,057</td>
<td>-</td>
</tr>
<tr>
<td>BBB</td>
<td>21,453</td>
<td>-</td>
</tr>
<tr>
<td>Lower than BBB</td>
<td>-</td>
<td>818</td>
</tr>
<tr>
<td>Not rated</td>
<td>6,037</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>75,319</strong></td>
<td><strong>3,350</strong></td>
</tr>
</tbody>
</table>

The non-rated category corporates includes predominantly externally managed fixed-income funds and loans issued to intermediaries. ASR Basis Ziektekostenverzekeringen N.V. applies stringent application and approval procedures to these loans. Following an intermediary’s application, their credit quality is determined based on an internal risk-rating model. The loan application is then submitted for approval to the Credit Committee.

C.2.6 Market risk concentrations

Concentration risk is the risk of an accumulation of exposures with the same counterparty.

ASR Basis Ziektekostenverzekeringen N.V. has an exposure to one counterparty which exceeds the Solvency II thresholds. This results in a limited amount of concentration risk.

C.3 Counterparty default risk

Counterparty default risk reflects possible losses due to unexpected default or deterioration in the credit standing of counterparties and debtors. Counterparty default risk affects several types of assets:
- receivables
- cash and deposits

Assets that are in scope of spread risk are, by definition, not in scope of counterparty default risk and vice versa.
The Solvency II regime makes a distinction between two types of exposures:

- **Type 1**: These counterparties generally have a rating (reinsurance, derivatives, current account balances, deposits with ceding companies and issued guarantee (letter of credit). The exposures are not diversified.
- **Type 2**: These counterparties are normally unrated (receivables from intermediaries and policyholders, mortgages with private individuals or SMEs). The exposures are generally diversified.

The total capital requirement for counterparty risk is an aggregation of the capital requirement for type 1 exposure and the capital requirement for type 2 exposure by taking 75% correlation.

<table>
<thead>
<tr>
<th>Counterparty default risk - required capital</th>
<th>31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 1</td>
<td>274</td>
</tr>
<tr>
<td>Type 2</td>
<td>8,147</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-67</td>
</tr>
<tr>
<td>Total</td>
<td>8,354</td>
</tr>
</tbody>
</table>

**C.3.1 Mortgages**

ASR Basis Ziektekostenverzekeringen N.V. has no mortgages on the balance sheet.

**C.3.2 Savings-linked mortgage loans**

ASR Basis Ziektekostenverzekeringen N.V. has no savings loans on the balance sheet.

**C.3.3 Derivatives**

ASR Basis Ziektekostenverzekeringen N.V. has no derivatives on the balance sheet.

**C.3.4 Reinsurance**

ASR Basis Ziektekostenverzekeringen N.V. has no reinsurance contracts on the balance sheet.

**C.3.5 Receivables**

<table>
<thead>
<tr>
<th>Receivables</th>
<th>31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policyholders</td>
<td>-</td>
</tr>
<tr>
<td>Intermediaries</td>
<td>3,917</td>
</tr>
<tr>
<td>Reinsurance operations</td>
<td>-</td>
</tr>
<tr>
<td>Health insurance fund</td>
<td>72,615</td>
</tr>
<tr>
<td>Other</td>
<td>31,270</td>
</tr>
<tr>
<td>Total</td>
<td>107,802</td>
</tr>
</tbody>
</table>

**C.3.6 Cash and deposits**

The current accounts amounted €1.5 million in 2016.

<table>
<thead>
<tr>
<th>Current accounts</th>
<th>31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAA</td>
<td>0%</td>
</tr>
<tr>
<td>A</td>
<td>100%</td>
</tr>
<tr>
<td>Lower than A</td>
<td>0%</td>
</tr>
</tbody>
</table>
C.4 Liquidity risk

Liquidity risk is the risk that ASR Basis Ziektekostenverzekeringen N.V. is not able to meet its financial obligations to policyholders and other creditors when they become due and payable, at a reasonable cost and in a timely manner. Liquidity risk is not quantified in the Solvency Capital Requirement of ASR Basis Ziektekostenverzekeringen N.V. and is therefore separately discussed here.

ASR Basis Ziektekostenverzekeringen N.V. recognizes different levels of liquidity management. Short-term liquidity, or daily cash management, covers the day-to-day cash requirements under normal business conditions and targets funding liquidity risk. Long-term liquidity management considers business conditions in which market liquidity risk materialises. Stress liquidity management looks at the ability to respond to a potential crisis situation as a result of a market event and an ASR Basis Ziektekostenverzekeringen N.V. specific event. Unexpected cash outflows could occur as result of lapses in the insurance portfolio. ASR Basis Ziektekostenverzekeringen N.V. monitors its liquidity risk scenarios via different risk reporting and monitoring processes including daily cash management reports, cash flow forecasts and stress scenario liquidity reports.

ASR Basis Ziektekostenverzekeringen N.V.’s liquidity management principle consists of three components. First, a well-diversified funding base is necessary in order to provide liquidity for cash management purposes. A portion of assets must be invested in unencumbered marketable securities that can be used for collateralized borrowing or asset sales. Second, the strategic asset allocation should reflect the expected and contingent liquidity needs of liabilities. Finally, an adequate and up-to-date contingency liquidity plan is in place to enable management to act effectively and efficiently in times of crisis.

As at 31 December 2016, ASR Basis Ziektekostenverzekeringen N.V. had cash (€ 1.5 million), liquid government bonds (€ 93.7 million) and other bonds and shares.

The following table shows the contractual cash flows of assets and liabilities (excluding investments on behalf of policyholders and insurance contracts on behalf of policyholders).

<table>
<thead>
<tr>
<th>31 December 2016</th>
<th>&lt; 1 yr</th>
<th>1-5 yrs</th>
<th>5-10 yrs</th>
<th>10-20 yrs</th>
<th>&gt; 20 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed-income assets</td>
<td>236,483</td>
<td>136,052</td>
<td>8,735</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Liabilities</td>
<td>-1,929</td>
<td>-267,221</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>234,554</td>
<td>-131,169</td>
<td>8,735</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

With regard to liquidity risk, ‘the expected profit included in future premiums’ ("EPIFP") means the expected present value of future cash flows which result from the inclusion in technical provisions of premiums relating to existing insurance and reinsurance contracts that are expected to be received in the future, but that may not be received for any reason, other than because the insured event has occurred, regardless of the legal or contractual rights of the policyholder to discontinue the policy. The EPIFP 2016 for ASR Basis Ziektekostenverzekeringen N.V. is nil.

C.5 Operational risk

This paragraph contains a description of group policy, which is applicable for the solo entity. Operational Risk Management involves the management of all possible risks that may influence the achievement of the company targets and that can cause financial or reputational damage. Operational risk management includes the identification, analysis, prioritization and management of these risks in line with the risk appetite. The policy on operational risk management is drafted and periodically evaluated under the coordination of Enterprise Risk Management. The policy is implemented in the decentralized business entities under the responsibility of the management boards. A great number of risks is encountered with the operational risk management policy: IT risk, outsourcing, data quality, claim handling etc.

The required capital for operational risk is presented below.
Identifying
With the operational targets as a starting point, each business entity performs risk assessments to identify events that could influence these targets. In each business entity the business risk manager facilitates the periodic identification of the key operational risks. All business processes are taken into account to identify the risks. All identified risks are prioritized and recorded in a risk-control framework.

In some areas, the risk policies prescribe specific risk analyses to be performed to identify and analyze the risks. For important IT systems, SPRINT analyses have to be performed and also for large outsourcing projects a specific risk analysis is required.

Measuring
All risks in the risk-control frameworks are assessed on probability of defaults and impact. Where possible, the variables are quantified, but often judgments of subject matter experts are required. Based on the estimation of the variables, each risk is labeled with a specific level of concern. Risks with a high level of concern are considered ‘key’.

Managing
For each risk, identified controls are implemented into the processes to keep the level of risk within the agreed risk appetite. In general, risks can be accepted, mitigated, avoided or transferred. A large range of options is available to mitigate operational risks, depending on the type. For each control an estimation is made of the net risk, after implementing the control.

Monitoring and reporting
The effectiveness of operational risk management is periodically monitored by the business risk manager at each business entity. For each control in the risk-control framework a testing calendar is established, based on accounting standards. Each control is tested regular and the outcomes on the effectiveness to manage the key risks are reported to the management board. Outcomes are also reported to the NFRC and a.s.r. Risk Committee.

Evaluating
Periodically, at least every year, the risk-control frameworks and operational risk management policies are evaluated to see if adjustments are desirable. The risk management function also challenges the business entities on their risk-control frameworks.

Operational incidents
Operational incidents with operational losses in excess of €5000 are reported to Group Risk Management, in accordance with the operational risk policy. The causes of losses are evaluated in order to learn from these experiences. An overview of main losses is reported to the NFRC. Actions are defined and implemented to avoid repetition of operational losses.

Information Communication Technology
Through IT risk management, a.s.r. devotes attention to the efficiency, effectiveness and integrity of Information Communication Technology (ICT). The logical access control for key applications used in the financial reporting process remains a high priority in order to enhance the integrity of applications of data. The logical access control procedures also prevent fraud by improving segregation of duties and by conducting regular checks of actual access levels within the applications. Proper understanding of information, security and cyber risks is essential, and this is why actions are carried out to create awareness among employees and business lines.

Business Continuity Management
Operational management can be disrupted significantly by unforeseen circumstances or calamities which could ultimately disrupt the execution of critical and operational processes. Business Continuity Management enables a.s.r. to continue its daily business uninterruptedly and to react quickly and effectively during such situations.

Critical processes and activities and the tools necessary to use for these processes, are identified during the Business Impact Analysis. This includes the resources required to establish similar activities at a remote location. The factors that can threaten the availability of those tools necessary for the critical processes are identified in the Threat Analysis.
a.s.r. considers something a crisis when one or more business lines are (in danger of being) disrupted in the operational management, due to a calamity, or when there is a reputational threat. In order to reduce the impact of the crisis, to stabilize the crisis, and to be able to react timely, efficiently and effectively, a.s.r. has assigned a crisis organization.

Each business line has their own crisis team led by the director of the management team. The continuity of activities and the recovery systems supporting critical activities are regularly tested and crisis teams are trained annually. The objective of the training is to give the teams insights into how they function during emergencies and to help them perform their duties more effectively during those situations. The training also sets out to clarify the roles, duties and responsibilities of the crisis teams.

Recovery Planning
a.s.r.’s Recovery Plan helps to be prepared and have the capacity to act in various forms of extreme financial stress. To this end, the Recovery plan describes and quantifies the measures that can be used to get through a crisis situation. These measures are tested in the scenario analysis, in which the effects of each recovery measure on a.s.r.’s financial position (solvency and liquidity) are quantified. The required preparations for implementing the measures, their implementation time and effectiveness, potential obstacles and operational effects are also assessed. The main purpose of the Recovery Plan is to increase the likelihood of successful early intervention during a financial crisis situation and to further guarantee that the interest of policyholders and other stakeholders are protected.

Reasonable assurance and model validation
a.s.r. aims to obtain reasonable assurance regarding the adequacy and accuracy of the outcomes of models that are used to provide best estimate values and solvency capital requirements. To this end, multiple instruments are applied, including model validation. Materiality is determined by means of an assessment of impact and complexity. Impact and complexity is expressed in terms of High (H), Medium (M), or Low (L).

In the pursuit of reasonable assurance, model risk is mitigated and unpleasant surprises are avoided, against acceptable costs.

C.6 Other material risks
As part of the regular ORSA process, the overall risk profile and associated solvency capital needs are assessed against ASR Basis Ziektekostenverzekeringen N.V.’s actual solvency capital position, taking into account identified risks that are not incorporated into the standard formula. The following risks are recognized by ASR Basis Ziektekostenverzekeringen N.V. as being potentially material:

- Inflation risk
- Reputation risk
- Liquidity risk
- Contagion risk
- Legal environment risk
- Model risk
- Strategic risk
- Non-insurance related risk
- New and upcoming risk

The most important risks to which ASR Basis Ziektekostenverzekeringen N.V. is exposed, including risks that are not incorporated into the standard formula, are identified through a combined top-down (strategic risk assessment) and bottom-up (control risk self-assessments) approach. After assessment of the effectiveness of the mitigating measures, the risks with the highest ‘Level of Concern’ or LoC are translated to the a.s.r. risk priorities and relevant risk scenarios for the ORSA.
C.7 Any other information

C.7.1 Description of off-balance sheet positions

Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

C.7.2 Reinsurance policy and risk budgeting

C.7.2.1 Reinsurance policy
ASR Basis Ziektekostenverzekeringen N.V. does not reinsure any specific underwriting risk at this moment.

C.7.2.2 Risk budgeting
The FRC assesses the solvency position and the financial risk profile on a monthly basis. Action is taken where appropriate to ensure the predefined levels in the risk appetite statement will not be violated.

C.7.3 Monitoring of new and existing products

This paragraph contains a description of group policy, which is applicable for the solo entity. Group Risk Management, Integrity and Legal Affairs participate in the product approval committee (PARP). All these departments evaluate whether risks in newly developed products are sufficiently addressed. New products need to be developed in a way that they are cost efficient, reliable, useful and secure. New products must also be strategically aligned with ASR Basis Ziektekostenverzekeringen N.V.’s mission to be a solid and trustworthy insurer. In addition, the risks of existing products are evaluated, as requested by the PARP, as a result of product reviews.
D Valuation for Solvency purposes

This chapter contains information regarding the valuation of the balance sheet items. For each material asset class the bases, methods and main assumptions used for valuation for solvency purposes are described. Separately for each material class of assets a quantitative and qualitative explanation of any material difference between the valuation for solvency purposes and valuation in the financial statements. When accounting principles are equal or when line items are not material, some line items are clustered together.

Valuation of assets is based on fair value measurement as described below. Each material asset class is described in paragraph D.1. Valuation of technical provisions is calculated as the sum of the best estimate and the risk margin. This is described in paragraph D.2. Other liabilities are described in paragraph D.3.

Information for each material line item is based on the balance sheet below. For each line item is described:
• Methods and assumptions for valuation
• Difference between solvency valuation and valuation in the financial statements

The numbering of the line items refer to the comments below.
Based on the differences in this template a reconciliation is made between IFRS equity and Solvency equity.

<table>
<thead>
<tr>
<th>Balance sheet</th>
<th>31 December 2016 IFRS</th>
<th>Revaluation</th>
<th>31 December 2016 Solvency II</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Goodwill, DAC, and Intangible assets</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2. Deferred tax assets</td>
<td>3,594</td>
<td>-404</td>
<td>1,191</td>
</tr>
<tr>
<td>3. Property, plant, and equipment held for own use</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4. Investments - Property (other than for own use)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5. Investments - Holdings in related undertakings, including participations</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6. Investments - Equity</td>
<td>193</td>
<td>193</td>
<td>193</td>
</tr>
<tr>
<td>7. Investments - Bonds</td>
<td>265,197</td>
<td>-</td>
<td>265,197</td>
</tr>
<tr>
<td>8. Investments - Collective Investments Undertakings</td>
<td>6,037</td>
<td>-</td>
<td>6,037</td>
</tr>
<tr>
<td>9. Investments - Derivatives</td>
<td>51</td>
<td>-</td>
<td>51</td>
</tr>
<tr>
<td>10. Investments - Deposits other than cash equivalents and other investments</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>11. Unit-linked investments</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>12. Loans and mortgages</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>13. Reinsurance recoverables</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>14. Receivables</td>
<td>115,641</td>
<td>-1,871</td>
<td>114,770</td>
</tr>
<tr>
<td>15. Cash and cash equivalents</td>
<td>1,549</td>
<td>-</td>
<td>1,549</td>
</tr>
<tr>
<td>16. Any other assets, not elsewhere shown</td>
<td>4,384</td>
<td>-29</td>
<td>4,355</td>
</tr>
<tr>
<td>Total assets</td>
<td>396,646</td>
<td>-3,250</td>
<td>393,396</td>
</tr>
<tr>
<td>17. Technical provisions (best estimates)</td>
<td>265,539</td>
<td>-18,671</td>
<td>246,868</td>
</tr>
<tr>
<td>18. Technical provisions (risk margin)</td>
<td>-</td>
<td>8,210</td>
<td>8,210</td>
</tr>
<tr>
<td>19. Unit-linked best estimate</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>20. Unit-linked risk margin</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>21. Pension benefit obligations</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>22. Deferred tax liabilities</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>23. Subordinated liabilities</td>
<td>10,000</td>
<td>-</td>
<td>10,000</td>
</tr>
<tr>
<td>24. Other liabilities</td>
<td>6,782</td>
<td>-</td>
<td>6,782</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>282,321</td>
<td>-10,460</td>
<td>271,861</td>
</tr>
<tr>
<td>Excess of assets over liabilities</td>
<td>114,325</td>
<td>7,211</td>
<td>121,536</td>
</tr>
</tbody>
</table>
This chapter contains also the reconciliation between the excess of assets over liabilities to EOF.

<table>
<thead>
<tr>
<th>x1000</th>
<th>Gross of tax</th>
<th>Net of tax</th>
<th>31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total equity IFRS</strong></td>
<td></td>
<td></td>
<td><strong>114,325</strong></td>
</tr>
<tr>
<td><strong>Revaluation of other assets</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intangible assets</td>
<td>-29</td>
<td>-22</td>
<td></td>
</tr>
<tr>
<td>Investments - Holdings in related undertakings, including participations</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Savings-linked mortgages</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Mortgages</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Loans</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Receivables</td>
<td>-817</td>
<td>-612</td>
<td>-635</td>
</tr>
<tr>
<td><strong>Revaluation of the technical provisions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFRS technical provisions cancelling</td>
<td>265,539</td>
<td>199,154</td>
<td></td>
</tr>
<tr>
<td>Best Estimate Solvency II accounting</td>
<td>-246,868</td>
<td>-185,151</td>
<td></td>
</tr>
<tr>
<td>Risk margin accounting</td>
<td>-8,210</td>
<td>-6,158</td>
<td></td>
</tr>
<tr>
<td>Cancelling of the reinsurers part in the IFRS technical provisions</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Accounting of the reinsurers part in the technical provisions</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>Own funds Solvency II</strong></td>
<td></td>
<td></td>
<td><strong>121,536</strong></td>
</tr>
<tr>
<td>Subordinated liabilities</td>
<td>-</td>
<td>10,000</td>
<td></td>
</tr>
<tr>
<td>Foreseeable dividends and distributions</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Deductions for participations in financial and credit institutions</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>Eligible Own funds Solvency II</strong></td>
<td></td>
<td></td>
<td><strong>131,536</strong></td>
</tr>
</tbody>
</table>

### D.1 Assets

Valuation of most financial assets is based on fair value. In the paragraph below, this valuation methodology is described. For different line items will be referred to this method. In this paragraph line items 1 – 15 from the simplified balance sheet above are described.

#### D.1.1 Fair value measurement

In accordance with the Delegated Regulation, Solvency II figures are based on fair value. In line with the valuation methodology described in article 75 and further of the Solvency II directive and articles 9 and 10 , the following three hierarchical levels are used to determine the fair value of financial instruments and non-financial instruments when accounting for assets and liabilities at fair value:

**Level 1: Fair value based on quoted prices in an active market**

Level 1 includes assets and liabilities whose value is determined by quoted (unadjusted) prices in the primary active market for identical assets or liabilities.
A financial instrument is quoted in an active market if:

- quoted prices are readily and regularly available (from an exchange, dealer, broker, sector organization, third party pricing service or a regulatory body); and
- these prices represent actual and regularly occurring transactions on an arm's length basis.

**Level 2: Fair value based on observable market data**

Determining fair value on the basis of Level 2 involves the use of valuation techniques that use inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices of identical or similar assets and liabilities). These observable inputs are obtained from a broker or third party pricing service and include:

- quoted prices in active markets for similar (not identical) assets or liabilities;
- quoted prices for identical or similar assets or liabilities in inactive markets;
- input variables other than quoted prices observable for the asset or liability. These include interest rates and yield curves observable at commonly quoted intervals, volatility, early redemptions spreads, loss ratio, counterparty default risks and default percentages.

**Level 3: Fair value not based on observable market data**

At Level 3, the fair value of the assets and liabilities is determined using valuation techniques for which significant inputs are not based on observable market data. In these situations, there can also be marginally active or inactive markets for the assets or the liabilities. The financial assets and liabilities in this category are assessed individually.

Valuation techniques are used to the extent that observable inputs are not available. The basic principle of fair value measurement is still to determine a fair, arm's length price. Unobservable inputs therefore reflect management's own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). These inputs are generally based on the available observable data (adjusted for factors that contribute towards the value of the asset) and own source information. In the unlikely event that the fair value of a financial instrument cannot be measured, it is carried at cost.

**D.1.2 Per asset category**

The balance sheet reports specify different asset categories. In this section, we describe the valuation of each material asset category. The figures correspond to the extended balance sheet which has been reported as QRT S 2.01.

1. **Goodwill and Intangible assets**
   The intangible assets relate to Goodwill, pre-paid commissions and other intangible assets are not recognized in the Solvency II framework and are set to nil.

2. **Deferred tax asset**
   The basis for the DTA / DTL position in the IFRS balance sheet is temporary differences between fiscal and commercial valuation. This DTA / DTL position is the base for this line item on the Solvency II balance sheet, adjusted for Solvency II revaluations, such as revaluation of technical provisions.

   In accordance with the Delegated Regulation the DTA / DTL position is netted in the balance sheet. The balance sheet of ASR contains a DTA.

   The deferred tax effects involve a correction related to the fact that (most of) the revaluations as described in this chapter are gross of tax. The tax effect is calculated as 25%.

   The calculation takes into account that some differences are exempted of tax.

3. **Property plant, and equipment held for own use**
   Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

4. **Investments - Property (other than for own use)**
   Not applicable for ASR Basis Ziektekostenverzekeringen N.V.
5. Investments - Holdings in related undertakings, including participations
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

6. Investments – Equity
Not material for ASR Basis Ziektekostenverzekeringen N.V.

7. Investments – Bonds
The valuation of these assets is consistent with the IFRS fair value hierarchy as described in paragraph D.1.1.

8. Investments - Collective investment undertakings
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

9. Investments – Derivatives
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

10. Investments - Deposits other than cash equivalents and other investments
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

11. Assets held for index-linked and unit-linked funds
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

12. Loans and mortgages
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

13. Reinsurance recoverables
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

14. Receivables (trade not Insurance)
The fair value of receivables is based on the level 2 method of the fair value hierarchy. The fair value is based on the discounted cash flow method. It is obtained by calculating the present value based on expected future cash flows and assuming an interest rate curve used in the market that includes an additional spread based on the risk profile of the counterparty.

15. Cash and cash equivalents
The valuation of cash and cash equivalents is based on the level 1 method of the fair value hierarchy. Cash and cash equivalents include cash in hand, deposits held at call with banks, cash collateral and other short-term highly liquid investments with original maturities of three months or less.

16. Any other assets, not elsewhere shown
The valuation of these assets is based on the IFRS fair value hierarchy as described in paragraph Section D.1.1. Other assets include different investments and interest income, property developments, tax assets and accrued assets.

Discontinued operations
Discontinued operations are recognized on the IFRS Balance sheet as a single line item. These assets are recognized on a line by line basis in the Solvency II balance sheet.

D.2 Technical provisions

D.2.1 Introduction
In this section, the policies regarding methodology and assumptions for the technical provisions are described. These liabilities arise from insurance contracts issued by ASR Basis Ziektekostenverzekeringen N.V.
D.2.2 Technical provisions methods

D.2.2.1 Medical expense insurance
What follows is a description of the policies, methods and principal assumptions that were decisive in determining the value of the technical provisions and the risk margin.

Composition of homogeneous risk group for ASR Basis Ziektekostenverzekeringen N.V. (BV)
A homogeneous risk group (HRG) encompasses a collection of policies with similar risk characteristics as stipulated by Solvency II, which are generally recorded separately. For the BV the coverage is determined by the national government. Therefore all the coverages are the same for all labels and distribution channels. Also, the BV is a mandatory insurance for all inhabitants in The Netherlands. For these two reasons one HRG is defined.

Contract boundary
The government decides on the basic health insurance package every year and this package is mandatory for all inhabitants of The Netherlands. The composition of this package may be different from year to year. In addition, the contract boundary of an insurance contract is just one calendar year which is laid down in law. Insured persons are free to accept or reject a new offer from their health insurer after one year. The composition of the portfolio changes mainly because of insured persons switching health insurers. Claims incurred during the period of cover continue to be insurance liabilities for the covering health insurer. The insurance portfolio and hence the risk profile stays stable during one year, because of the breakdown by claim year.

Risk equalization model
The Dutch Health Insurance is laid down in law (Zvw) and is supplemented by a risk equalization model which is performed by the National Health Care Institute (ZINL) for the basis insurance contract (BV).

The risk equalization model compensates health insurers for differences in the composition of their insured population creating a level playing field. All health insurance companies receive an equalization premium from ZINL on an annual basis, of which the amount depends on the insured population. The insurance companies receive the equalization premiums for every underwriting year over a period of two years according to a pre-defined payment schedule. The equalization premium is estimated beforehand by ZINL and is corrected afterwards based on the realized insured population. The equalization premium is determined definitively after 4.5 years. The estimated equalization premium beforehand is called “ex ante” and the difference between ex ante and the corrected realized equalization premium is called “ex post”.

The equalization premium should cover 50% of all health expenses nationally. The second 50% should be covered by a commercial premium per person above eighteen, calculated by each health insurer independently.

D.2.2.2 Bases and methods
Best estimate claim provision BV
The inflation method is used for the first months of the new year because little is known about the use of health care and its declaration pattern of the new year. The inflation rate is based on the existing contracts from the previous year which are under negotiation for new year and market rates for health care consumption.

The outstanding claims provisions for basic health insurance are determined by the health care purchasing method. This method that has been applied for calculating the best estimate claims provisions for Specialist Medical Care (MSZ) and Mental Health Care (GGZ) is based on contractual tariff agreements per claim year with individual health institution like hospitals and mental health care institutions. MSZ and GGZ determined more than 65% of the total best estimate provisions. In almost all the contractual agreements a maximum of claims amount has been formalized between ASR BV and the health institution. The health institution is allowed to invoice their claims until the maximum is reached. If the claims exceed the maximum, a.s.r. can retrieve the amount above the maximum. This amount is called revenue settlement. By using this method the individual risk (claims) per health institution can be monitored and managed.

6 Zvw: Zorgverzekeringswet
7 In Dutch: Opbrengstverrekening
The outstanding claims provisions for all the other health care services\(^8\) are determined using a Development Factor Model in combination with the Bornhuetter-Ferguson method for each claim year. The other health care services consists of General Practitioner, Pharmacy, Oral Care, Obstetrics, Paramedical Care, Medical Aids, Patient Transport, Maternity Care, Other Services, Specialist Medical Care. The expected cash flow for ex post may be a benefit of ZINL or a claim of ZINL and is part of the claim provision. Once a benefit or claim of ex post has determined it is accountable to a certain year and therefore attributed to the cash flow of the concerning year.

The best estimate claims provision is discounted at the interest rate term structure (zero coupon curve) prescribed by EIOPA. The prevailing yield curve is set internally at group level.

**Cash flows BV**

The cash flow pattern of the claim provisions is based on the history of paid claims in a chain ladder model at the level of health type\(^9\) aggregated per year and quarter.

**Best estimate of premium provision BV**

The best estimate for the premium provision is determined using estimated future cash flows from portfolio growth, premium income (commercial and equalization premium), claims payments and claims handling costs as included in the premium determination and sales results for the new insurance year. This relates to the next 12-month insurance period (one year contract boundary) and serve as the benchmark for the scale of the premium provision on the reference date.

The cash flow pattern of the future claim provision is based on paid claims in a chain ladder model. The assumptions are:

A. Claims received in past months are predictive for the future payment pattern of claims.
B. The payment patterns are constant / equal divided for the coming months to year end.
C. The payment pattern for the future claims is equal to the payment pattern of the current (already) paid claims

The same yield curve, which a.s.r. sets internally at group level and subsequently supplied to the supervised entity, is used as for the outstanding claims provisions.

**Claims handling costs BV**

The cash flows for claims handling costs are proportional to the cash flows of the paid claims for the claim provisions. The percentage of claim handling costs is equal to the ratio ‘released claims handling costs at the end of year T-1 divided by paid claims including own risk at the end of year T-1 independent of claim years. This fixed percentage is applied to the outstanding claims provision for the current year in the reporting period (t) and for earlier years (t-1, t-2... t-n), and to the outstanding claims provision for future years in earlier years. The result is the provision for claims handling costs. The provision for claims handling costs is included in the best estimate for the outstanding claims and premium provisions. The remaining (other) costs are paid uniformly in an year.

**Risk margin methodology**

The insurance risks have been determined in accordance with the standard formula described in the Delegated Acts. Group a.s.r. applies the Cost of Capital method that is applicable to BV and AV as well with a Cost of Capital rate of 6%.

**Risk Drivers risk margin**

In the calculation of the risk margin is a projection made of the underlying risks with certain risk drivers. It involves the following risks:

- **Premium and reserve risk**
  - The risk driver for the premium and reserve risk is the SCR premium and reserve risk. The input for the SCR is the volume measure premium risk and volume measure reserve risk. The volume measure of premium risk has a projection for one year (T) in accordance with the contract boundary of 1 year. The volume measure (best estimate) reserve risk has a projection from year T and subsequent years (T + n).

- **Counterparty risk**
  - The risk driver for counterparty risk is determined by the volume measure equal to the total amount of debtors position. Each reporting period (Quarter) a new debtor position is used.

---

\(^8\) Other health care services is in Dutch Rest Zorg

\(^9\) For example a health type is: General Practitioner, Pharmacy, Oral Care, Obstetrics, Specialist Medical Care, Paramedical Care, Medical Aids, Patient Transport
• Catastrophe risk
The risk driver for catastrophe risk is the SCR catastrophe risk. A catastrophe is an unexpected future event with a duration of one year. The risk is determined ultimo year. The amount of SCR catastrophe risk is apparent from the number of insured and parameters for mass casualty and pandemic that have been approved by DNB in consultation with Health Insurers Netherlands. The catastrophe risk has a projection of one year (T) following from the contract boundary of one year in accordance with the Dutch Health Insurance Act for Health Insurance. After year T the risk is ‘zero’. Catastrophe risk for AV equals zero.

• Operational risk
a.s.r. medical expenses applies the methodology of group a.s.r. for determining the risk driver for operational risk. The operational risk is quantified by taking the highest amount of the technical provision or the premium volume of the past 12 months. The risk driver for year T is the SCR Operational risk and for future years is the ratio of the BSCR year T + 1 / BSCR year T multiplied by the SCR Operational risk in year T.

<table>
<thead>
<tr>
<th></th>
<th>VA = 13 bp</th>
<th>VA = 0 bp</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>TP</td>
<td>255,078</td>
<td>255,810</td>
<td>732</td>
</tr>
<tr>
<td>SCR</td>
<td>91,158</td>
<td>91,624</td>
<td>466</td>
</tr>
<tr>
<td>MCR</td>
<td>37,271</td>
<td>37,305</td>
<td>34</td>
</tr>
<tr>
<td>Basic own funds (total)</td>
<td>131,536</td>
<td>130,987</td>
<td>-549</td>
</tr>
<tr>
<td>Eligible own funds</td>
<td>131,536</td>
<td>130,987</td>
<td>-549</td>
</tr>
</tbody>
</table>

Table: impact of applying VA = 0 bps

D.2.3 Level of uncertainty

This paragraph contains a description of group policy, which is applicable for the solo entity. a.s.r. distinguishes between two sources of uncertainty with regard to the level of the technical provisions. These sources are model risk and process risk. The uncertainty associated with these risks has been mitigated as described below.

Process risk
The process risk is mitigated using the Management in Control framework (MIC), which creates a reasonable degree of assurance as to the reliability of financial reports. Key controls have been identified and to a larger extend implemented for the calculation process. In addition, the effectiveness of the MIC framework is verified by an independent party and supplementary checks are performed where needed. As part of MIC or the additional checks, the four-eye principle has demonstrably been applied to the calculation of the technical provision.

Model risk
The second risk that a.s.r. has identified in relation to the technical provisions is model risk. Regular procedures have provided adequate certainty with regard to this risk. To illustrate, a model validation process mitigates the risk of material misstatements or that key facts have been omitted. In addition, FRM, in its role as the second line of defence, performs an independent internal review of the technical provisions as described in the previous phase.

D.2.4 Reinsurance and special purpose vehicles (SPVs)
Not applicable to ASR Basis Ziektekostenverzekeringen N.V.

D.2.5 Technical provisions

In this table a reconciliation is made between the SII and the IFRS valuation of provisions. Solvency figures are part of the Balance Sheet S 2.01. The next paragraph describes a brief explanation of these differences.

<table>
<thead>
<tr>
<th></th>
<th>31 December 2016 IFRS</th>
<th>31 December 2016 Solvency II</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Revaluation</td>
<td></td>
</tr>
<tr>
<td>Similar to non-life</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Best estimate</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Risk margin</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
D.2.6 Reconciliation between IFRS and Solvency II

Under Solvency II, the technical provisions are calculated using a different method compared to IFRS. In this section the reconciliation between IFRS and Solvency II is described per business line.

Similar to non-life
The revaluation for similar to non-life (medical expense) is caused by:
- The effect of discounting the outstanding claims and premium provisions: €0.4 million
- Unexplained difference between IFRS and Solvency II: €-0.4 million
- Before disclosure of Solvency II, new information results in a shift from premium provision to claim provision under Solvency II: 6.6 million.
- The IFRS LAT margin: -€9.6 million.

D.3 Other liabilities

D.3.1 Valuation of other liabilities

In line with the valuation of assets, the accounting principles for other liabilities used in the Pillar III reports are generally also based on the IFRS as adopted by the EU. Any differences between the valuation methods for IFRS and Solvency II purposes are addressed in detail per liability category. In this paragraph line items 21 – 23 from the simplified balance-sheet above are described

21. Pension benefit obligations
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

On group level a.s.r. has in place a number of defined benefit plans for own staff. Current service costs for the OTSO’s are included in operating expenses.

22. Deferred tax liabilities
The basis for the DTA / DTL position in the IFRS balance sheet is temporary differences between fiscal and commercial valuation. This DTA / DTL position is the base for this line item on the Solvency II balance sheet, adjusted for Solvency II revaluations:
- The largest DTL mutation is caused by the higher (valuation) Mortgages and Savings Unloading
- The largest DTA mutations are mainly caused by the (lower) valuation of technical provisions

In accordance with the Delegated Regulation the DTA / DTL position is netted in the balance sheet. The balance sheet of ASR Basis Ziektekostenverzekeringen N.V. contains a DTA.

23. Subordinated liabilities
In IFRS the perpetual hybrid loans are classified as equity as there is no requirement to settle the obligation in cash or another financial asset or to exchange financial assets or financial liabilities under conditions that are potentially unfavourable for ASR Basis Ziektekostenverzekeringen N.V.

Directed by the regulator in Solvency reporting the perpetual hybrid loans are classified as subordinated liabilities.

24. Other liabilities
Other Liabilities contains different small line items:

Insurance and Intermediaries payables
The valuation of these liabilities follows the Solvency II fair value hierarchy as described in paragraph D.1.1 This category is subject to the same valuation as the asset category Cash and Cash equivalents.
Trade payables (non-insurance)
The valuation of these liabilities follows the Solvency II fair value hierarchy as described in paragraph D.1.1. This category is subject to the same valuation as the asset category receivables.

Any other liabilities not disclosed elsewhere
The valuation of these liabilities follows the Solvency II fair value hierarchy as described in paragraph D.1.1. This item consists primarily of tax payables.

Contingent liabilities
Contingent liabilities are defined as:
- a possible obligation depending on whether some uncertain future event occurs, or
- a present obligation but payment is not probable or the amount cannot be measured reliably.

Contingent liabilities are recognized on the IFRS balance sheet if there is a probability of >50% that the contingent liability leads to an “outflow of resources”. These liabilities are also recognized on the Solvency II balance sheet.

Solvency II prescribes that all contingent liabilities be recognized on the Solvency II balance sheet. This covers cases where the amount cannot be measured reliably or when the probability is <50%. For these cases, a regular process is in place to determine whether contingent liabilities should be recognized on the Solvency II balance sheet.

The ASR Basis Ziektekostenverzekeringen N.V. Solvency II capital ratio does not include contingent liabilities.

D.3.2 Reconciliation from Solvency II equity to EOF
The differences described in the above sections are the basis for the reconciliation of IFRS equity to equity Solvency II. To reconcile from Solvency II Equity to EOF, the following movements are taken into consideration:

Subordinated liabilities
In accordance with the Delegated Regulation the subordinated liabilities are part of the EOF. Further information of this liabilities is described in section E.

Foreseeable dividends and distributions
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

Deductions for participations in financial and credit institutions
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.

Tier 3 Limitation
In accordance with the Delegated Regulation EOF is divided in tiering components. There are boundary conditions related to the size of these components. Excess of this limits results in capping of EOF. For ASR Basis Ziektekostenverzekeringen N.V. capping does not apply per Q4 2016.

D.4 Alternative methods for valuation
ASR Basis Ziektekostenverzekeringen N.V. does not apply alternative methods for valuation.

D.5 Any other information
Not applicable for ASR Basis Ziektekostenverzekeringen N.V.
E Capital management

Key figures

Eligible own fund 2016

The solvency ratio stood at 144% as at 31 December 2016 based on the standard formula as a result of €131,536 thousand EOF and €91,158 thousand SCR.
E.1 Own funds

E.1.1 Capital management objectives

Management
Overall capital management is administered at Group level. The legal entities are capitalised separately. For ASR Basis Ziektekostenverzekeringen NV no upstreaming of capital or dividend to the Group level is currently foreseen. All capital present is used for strengthening of the capital positioning, investments or to maintain a socially responsible pricing level. With this strategy, a.s.r. takes into account the social sentiment with regard to the compulsory basis health insurance in The Netherlands and acts in line with capital- and pricing strategies of other health care insurers. Moreover, current legislation prohibits health care insurers to sell the basic health care insurance with the objective to make profit for shareholders.

Objectives
The Group is committed to maintain a strong capital position in order to be a robust insurer for its policyholders and other stakeholders. The objective is to maintain a solvency level that is within the limits defined in the risk appetite statements and the solvency targets. Sensitivities are periodically performed for principal risks and annual stress tests are performed to test a.s.r.’s robustness to withstand moderate to severe scenarios. An additional objective is to achieve a combination of a capital position and a risk profile that is at least in line with a single A Standard & Poor’s rating.

a.s.r. uses an Economic Capital (ECAP) model for the allocation of market risk budgets. This model applies a full look-through principle to the assets and the relevant risks.

The SCR is reported on a quarterly basis and proxies are made on a monthly basis. The internal minimum solvency ratio for ASR Basis Ziektekostenverzekeringen N.V. as formulated in the risk appetite statement is 110%. ASR Basis Ziektekostenverzekeringen N.V. does not have a management target. The solvency ratio stood at 144% at 31 December 2016, which was comfortably higher than the internal requirement of 110%.

In accordance with a.s.r.’s dividend policy, the liquidity of the underlying entities is not taken into account for the liquidity position of the group. However, the capital is recognized in the capital position of the group, since a.s.r. has the ability to realize the capital of this OTSO, for example by selling the entity. Specifically regarding ASR Basis Ziektekostenverzekeringen N.V. in 2016, no dividend or capital withdrawals have taken place. This practice is in accordance with the before mentioned policies regarding capital management for ASR Basis Ziektekostenverzekeringen N.V.
E.1.2 Tiering own funds

The table below details the capital position of ASR Basis Ziektekostenverzekeringen N.V. as at the dates indicated. With respect to the capital position, Solvency II requires the insurers to categorize own funds into the following three tiers with differing qualifications as eligible available regulatory capital:

- Tier 1 capital consists of Ordinary Share Capital and Reconciliation reserve.
- Tier 2 capital consists of ancillary own funds and basic Tier 2. Ancillary own funds consist of items other than basic own funds which can be called up to absorb losses. Ancillary own fund items require the prior approval of the supervisory authority. ASR Basis Ziektekostenverzekeringen N.V. has no ancillary own fund items.
- Tier 3 consists of Deferred tax assets.

The rules impose limits on the amount of each tier that can be held to cover capital requirements with the aim of ensuring that the items will be available if needed to absorb any losses that might arise.

<table>
<thead>
<tr>
<th></th>
<th>31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tier 1 capital - unrestricted</td>
<td>120,345</td>
</tr>
<tr>
<td>Tier 1 capital - restricted</td>
<td>-</td>
</tr>
<tr>
<td>Tier 2 capital</td>
<td>10,000</td>
</tr>
<tr>
<td>Tier 3 capital</td>
<td>1,191</td>
</tr>
<tr>
<td><strong>Eligible own funds to meet SCR</strong></td>
<td><strong>131,536</strong></td>
</tr>
</tbody>
</table>

The perpetual hybrid loans are classified as equity, as there is no requirement to settle the obligation in cash or another financial asset or to exchange financial assets or financial liabilities under conditions that are potentially unfavourable for ASR Basis Ziektekostenverzekeringen N.V. To be sure that the perpetual hybrids may be classified under Own Funds, terms and notes are proposed with Dutch Central Bank. Tiering is also part of this consultation.

E.1.3 Own funds versus MCR

The MCR calculation is based on the standard formula.

<table>
<thead>
<tr>
<th></th>
<th>31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tier 1 capital - unrestricted</td>
<td>120,345</td>
</tr>
<tr>
<td>Tier 1 capital - restricted</td>
<td>-</td>
</tr>
<tr>
<td>Tier 2 capital</td>
<td>7,454</td>
</tr>
<tr>
<td>Tier 3 capital</td>
<td>-</td>
</tr>
<tr>
<td><strong>Eligible own funds to meet MCR</strong></td>
<td><strong>127,799</strong></td>
</tr>
</tbody>
</table>

The eligible own funds to meet the MCR are lower than for the SCR due to tiering restrictions.

E.1.4 Description of grandfathering

Grandfathering is not applicable for ASR Basis Ziektekostenverzekeringen N.V.

E.2 Solvency Capital Requirement

ASR Basis Ziektekostenverzekeringen N.V. complied during 2016 with the applicable externally imposed capital requirement. The table below presents the solvency ratio as at the date indicated.
<table>
<thead>
<tr>
<th></th>
<th>31 December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligible Own Funds Solvency II</td>
<td>131,536</td>
</tr>
<tr>
<td>Required capital</td>
<td>91,158</td>
</tr>
</tbody>
</table>

Solvency ratio: 144%

Under Solvency II it is permitted to reduce the required capital with the mitigating tax effects resulting from a 1 in 200 year loss (“Shock loss”). There is a mitigating tax effect to the extent that the Shock loss is deductible for tax purposes and can be compensated with taxable profits. This positive tax effect can only be taken into account when sufficiently substantiated (‘more likely than not’). ASR Basis Ziektekostenverzekeringen N.V. did not include a beneficial effect on its solvency ratio(s) due to the application of the LAC DT of 0%.

Relevant regulation and guidance (Delegated Acts, Level 3 guidelines, Dutch Central Bank Q&A’s and IAS12) is taken into account in the development of the LAC DT methodology.

E.3 Use of standard equity risk sub-module in calculation of Solvency Capital Requirement

Equity risk is applicable to ASR Basis Ziektekostenverzekeringen N.V.

E.4 Differences between Standard Formula and internal models

As r.s. solvency is governed by a standard formula, rather than the self-developed internal model. The Executive Board believes that this should enhance transparency and consistent interpretation.

E.5 Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement

As ASR Basis Ziektekostenverzekeringen N.V. has not faced any form of non-compliance with the Minimum Capital Requirement or significant non-compliance with the Solvency Capital Requirement during the reporting period or at the reporting date, no further information is included here.

E.6 Any other information

E.6.1 Dividend policy and capital actions

The Group has formulated its dividend policy in line with its current strategy. The Group and the underlying business entities intend to pay an annual dividend that creates sustainable long-term value for its shareholders. The Group and the underlying business entities aim to operate at a solvency ratio, calculated according to the standard formula, above a management threshold level. However, for ASR Basis Ziektekostenverzekeringen N.V. this management threshold is not applicable as legislation prohibits the distribution of profits of health insurers level.